Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

By identifying and targeting disease-specific neoepitopes with stable expression patterns, personalized cancer immunotherapy can effectively overcome tumor evasion and improve treatment outcomes for a wider patient population.

JP2024163123AActive Publication Date: 2024-11-21BIONTECH SE
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
JP2024128915
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-07-20
Filing Date
2024-08-05
Publication Date
2024-11-21
Estimated Expiration
2037-07-19

AI Technical Summary

Technical Problem

Current cancer treatments based on the law of averages are ineffective for most patients due to molecular heterogeneity, and personalized immunotherapy methods fail to target mutations that can evade immune surveillance, leading to potential relapse.

Method used

Identify disease-specific neoepitopes by determining the copy number and zygosity of mutated alleles in genes, focusing on neoepitopes that are less likely to be silenced or deleted, such as those in essential or driver genes, and using these as targets for immunotherapy.

Benefits of technology

Enhances tumor control by ensuring that immunotherapy targets stable, consistently expressed neoepitopes, reducing the likelihood of tumor evasion and improving treatment efficacy for a broader range of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163123000001
    Figure 2024163123000001
  • Figure 2024163123000002
    Figure 2024163123000002
  • Figure 2024163123000003
    Figure 2024163123000003
Patent Text Reader

Abstract

To provide: methods for determining whether neoepitopes that are only expressed in or on diseased cells are suitable disease-specific targets, such that the diseased cell is less likely to be able to escape immune surveillance; and use of the neoepitopes in providing an immune response against diseased cells expressing the neoepitopes.SOLUTION: The invention relates to a method for determining the suitability of a neoepitope resulting from a disease-specific mutation at an allele in a gene (mutated allele) as a disease-specific target, the method comprising determining, in a diseased cell or population of diseased cells, the copy number of the mutated allele encoding the neoepitope.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to methods for determining the suitability of disease-specific neoepitopes as disease-specific targets and the use of such identified suitable neoepitopes in immunotherapy specifically targeted to diseased tissues of a patient, such as tumor tissues expressing one or more of the identified suitable neoepitopes. [Background technology]

[0002] Cancer is the leading cause of mortality, accounting for one in four all deaths. Cancer treatment has traditionally been based on the law of averages, which best applies to the greatest number of patients. However, due to molecular heterogeneity in cancer, often less than 25% of treated individuals benefit from an approved therapy. Personalized medicine, based on individually tailored treatments for patients, is considered as a potential solution to the low efficacy and high cost of innovation in drug discovery.

[0003] Personalized cancer immunotherapy is emerging as a promising breakthrough in cancer treatment that has the potential to transform the standard of care for millions of cancer patients diagnosed annually worldwide. The integrative aspect of personalized cancer immunotherapy allows the immune system to target genetic abnormalities (mutations) that are unique to a patient's cancer. Such disease-specific mutations can code for neoepitopes, which are disease-specific targets. The most widespread genetic abnormalities suffered by cancer genomes, which can be used as disease-specific targets for personalized immunotherapy, are nonsynonymous single nucleotide variations (SNVs). Thus, accurate and thorough identification of a patient's SNVs in the coding regions of the genome is a crucial step in the process of producing personalized cancer immunotherapy.

[0004] However, as described herein, knowing the identity of disease-specific mutations is only part of the picture. Rather, complete genetic profiling of mutations requires knowledge of the exact number of copies (including both wild-type and mutated alleles) of the gene containing the mutation in diseased cells, e.g., tumor cells, the number of copies of the mutated allele in the tumor cells (referred to herein as the zygosity state of the mutation), and the degree of subclonality of the mutation in a sample of diseased cells, e.g., a tumor sample. Indeed, the copy number diversity occurring in diseased cells is a significant component of the genetic diversity in diseased cells across most disease indications. Moreover, the degree of copy number diversity, the identity of the genes affected by copy number diversity, and the exact genetic makeup of the copy number diversity are unique to each individual and can vary widely between individuals. See generally, Shlien and Malkin, 2009, Genome Med. 1:62; Yang et al., 2013, Cell 153:919-929. Precise knowledge of such genetic traits may be crucial for the selection of mutations that, when targeted, have the potential to confer immunity to tumor escape and thus global tumor control. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] European Patent No. 2 198 292(B1) [Patent Document 2] European Patent No. 2 002 016(B1) [Patent Document 3] European Patent Application Publication No. 2 835 752(A) [Patent Document 4] International Patent Application Publication No. WO 2014 / 014497 [Patent Document 5] WO 2014 / 138153 [Patent Document 6] WO 97 / 24447 [Patent Document 7] PCT / EP2006 / 009448

Patent document 8

Non-licensed literature

[0006]

Non-licensed literature 1

Non-licensed Document 2

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

Non-Patent Document 9

Non-Patent Document 10

Non-Patent Document 11

Non-Patent Document 12

Non-Patent Document 13

Non-Patent Document 14

Non-Patent Document 15

Non-Patent Document 16

Non-Patent Document 17

Non-Patent Document 18

Non-Patent Document 19

Non-Patent Document 27

Non-Patent Document 28

Non-Patent Document 29

Non-Patent Document 30

Non-Patent Document 31

Non-Patent Document 32

Non-Patent Document 33

Non-Patent Document 34

Non-Patent Document 35

Non-Patent Document 36

[0007] In order to maximize the effectiveness of personalized cancer immunotherapy and provide sustained tumor control for the majority of treated patients, the therapy must in some way circumvent the tumor's ability to evade immune surveillance, for example by silencing the expression of mutated targets, for example by deleting genes. If this problem is not addressed, immunotherapy runs the risk of relapse, because if the mutation is not expressed, for example deleted from the genome, immunotherapy cannot target the mutation. The selection of suitable neoepitopes that enhance tumor control would benefit any personalized immunotherapy approach that targets neoepitopes, regardless of how it is performed. Thus, there is a need in the art for a method to select neoepitopes resulting from disease-specific mutations that result in enhanced tumor control. [Means for solving the problem]

[0008] The present invention provides a method to overcome the deficiencies of the state of the art by providing a method for determining the suitability of neoepitopes resulting from disease-specific mutations in genes as disease-specific targets that, in the case of cancer, would result in enhanced tumor control, where affected tissues cannot easily evade immune surveillance. Once a suitable neoepitope is identified, such a suitable epitope can be used as a disease-specific target to induce a specific immune response in patients with the disease. For example, the disease can be cancer and potentially a primary tumor, and tumor metastases expressing the suitable neoepitope can be targeted for more effective treatment.

[0009] The present invention relates to a method for determining the suitability of a neoepitope resulting from a disease-specific mutation in an allele (mutated allele) in a gene as a disease-specific target, comprising determining the copy number of the mutated allele encoding the neoepitope in a diseased cell or a population of diseased cells. As used herein, the copy number can also be referred to as the zygosity state, such that if the copy number of the mutated allele is 4, the mutated allele has a zygosity state of 4. As used herein, an allele is a site in a genome that has a specific nucleotide identity, which identity can be the same in both the maternal and paternal copies of the genome (homozygous genotype), or the identity can be different in the maternal and paternal copies of the genome (heterozygous genotype). A mutated allele is an allele that has an identity that is different from the site in a corresponding normal genome, e.g., a genome derived from a non-diseased cell of the same individual, preferably a non-diseased cell of the same tissue type as the diseased cell (matched genome), due to a disease-specific mutation. A suitable neoepitope as a disease-specific target (suitable neoepitope), as used herein, is a neoepitope whose expression is unlikely to be downregulated or silenced (e.g., by deletion) by diseased tissue when targeted by the immune system, such that diseased tissue is unlikely to be able to avoid a response, preferably an immunological response, generated against the neoepitope, for example, by vaccination against the neoepitope or administration of immune cells capable of targeting (binding to) the neoepitope. In an embodiment, the copy number of the mutated allele may be the same as the copy number of the gene comprising the mutated allele, and thus the present invention also relates to a method for determining the suitability of a neoepitope resulting from a disease-specific mutation in a gene as a disease-specific target, comprising the step of determining the copy number of the gene carrying the disease-specific mutation in a diseased cell or a population of diseased cells.

[0010] In one embodiment, a high copy number of a mutated allele or gene with a disease-specific mutation indicates suitability as a disease-specific target for a neoepitope, such that the higher the copy number of a mutated allele or gene with a disease-specific mutation, the higher the suitability as a disease-specific target for a neoepitope. In one embodiment, if the copy number of a mutated allele or gene with a disease-specific mutation in a diseased cell is greater than 2, this indicates suitability as a disease-specific target for a neoepitope. In one embodiment, if the copy number of a gene with a disease-specific mutation is greater than 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or greater than 100, this indicates suitability as a disease-specific target for a neoepitope.

[0011] If not all copies of a gene with at least one mutated allele have the mutation, it is preferred that many copies of the gene have the mutated allele, i.e., a higher percentage of copies of the gene rather than a lower percentage have the mutated allele (higher fractional zygosity rather than lower). Thus, in certain embodiments, the mutated allele is found in a high percentage of copies of the gene with at least one mutated allele (zygosity), where the zygosity is the ratio of the number of copies of the mutated allele (zygosity state of the mutated allele) to the total number of copies of the nucleotide site to which the mutated allele is mapped, in particular to the reference genome or the corresponding wild-type genome or matched genome, i.e. the wild-type genome from the same individual. The higher the zygosity of copies of the mutated allele, the higher the suitability of the neoepitope as a disease-specific target. Preferably, the zygosity rate can be greater than 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95, and most preferably, the zygosity rate is 1, i.e., all copies of the gene in the affected cell have the mutated allele. When the zygosity rate is 1, there are no wild-type copies of the gene, so that the affected cell cannot revert to the expression of the corresponding wild-type epitope. As used herein, a rate of 1 is when the hypothesis that the genetic arrangement, e.g., copy number, zygosity state, of the mutated allele / gene is the same cannot be disproved by the data, i.e., is statistically consistent.

[0012] It is known that diseased tissues, such as tumors, may be heterogeneous in genetic makeup and gene expression, and therefore not all diseased cells in diseased tissues have the same copy number of genes and / or genes with at least one copy of the mutated allele (total copy number of genes) and / or copies of genes with mutated alleles, which may even be the case for disease-specific mutations themselves. Thus, it is preferable (higher clonal proportion rather than lower) if, for example, the copy number of the mutated allele and / or the splicing rate and / or the total number of copies of the nucleotide site to which the mutated allele is mapped turns out to be the same or similar in a high percentage of diseased cells in diseased tissues rather than a low percentage of diseased cells. The higher the percentage of diseased cells that have, for example, the same or similar copy number of the mutated allele and / or the splicing rate and / or the total number of copies of the nucleotide site to which the mutated allele is mapped, the higher the suitability of the neoepitope as a disease-specific target. For example, the clonal fraction can be at least 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or at least 0.9. In a preferred embodiment, all diseased cells in a diseased tissue have the same or similar copy number, i.e., the clonal fraction is 1, i.e., statistically consistent. As used herein, the same or similar copy number includes the same copy number, or a copy number within 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or less of the copy number or absolute copy number, with or without error correction.

[0013] Preferably, the clonal proportion of the mutation can be obtained by the proportion of diseased cells with the same or similar genetic arrangement of the mutation, the genetic arrangement of the mutation including the total number of copies of the nucleotide site where the mutation is mapped and the number of copies of the mutated allele. If the feature is present in all diseased cells to the extent that it cannot be statistically disproved by the available data, the feature is said to be fixed in the population of diseased cells. Preferably, a clonal proportion of 1 means that the genetic arrangement of the mutation is fixed in the population of diseased cells. Preferably, if the mutation is fixed in the population of diseased cells and the CNV affecting the site encoding the mutation is fixed in the population of diseased cells, the genetic arrangement of the mutation is fixed in the population of diseased cells. Preferably, if the total number of copies of the nucleotide site where the mutation is mapped is 2 and it is determined that the mutation present in the equilibrium region of the diseased (tumor) genome is fixed in the population of diseased cells, the genetic arrangement of the mutation is fixed.

[0014] The gene in which the disease-specific mutation is found can potentially be present in any gene in the genome. The preferred type of gene in which the mutation resulting in a suitable neo-epitope is found is a gene whose expression leads to the transformation of a cell into a cancerous phenotype, or whose lack of expression leads to a cancerous cell losing its cancerous phenotype, i.e., a gene whose expression contributes to tumor progression. Such genes are known as driver genes. Examples of driver genes for many types of tumors are well known. For example, a list of 291 high-confidence cancer driver genes acting on 3,205 tumors from 12 different cancer types is disclosed in Tamborero et al., 2013, Comprehensive identification of mutational cancer driver genes across 12 tumor types, Scientific Reports 3:2650. Further driver genes have been identified using methods disclosed in Youn et al., 2011, Identifying cancer driver genes in tumor genome sequencing studies, Bioinformatics 27(2):175-181; Sakoparnig et al., 2015, Identification of constrained cancer driver genes based on mutation timing, PLoS Comput. Biol. 11(1):e1004027; and Forbes et al., 2008, Current protocols in human genetics 10-11. Disease-specific mutations in driver genes may or may not contribute to the cancerous phenotype. Preferably, all copies of the driver gene found in the diseased cells have the disease-specific mutation. Also preferably, all cells in the diseased tissue are diseased cells in which all copies of the driver gene have the disease-specific mutation.

[0015] Another preferred type of gene is an essential gene. In an embodiment, an essential gene is a gene that, when silenced or its expression is reduced (e.g., by deletion), at least leads to impaired growth or reduced fitness of a cell, preferably a diseased cell. Such genes are herein named essential genes. In one embodiment, an essential gene is a gene that exhibits at least a 10% reduced growth or reduced fitness in a diseased cell in which the gene is silenced or its expression is reduced, compared to a cell in which the gene is not silenced or reduced. In one embodiment, the reduced growth or reduced fitness is at least 20%, 30%, 40%, 50%, 60%, 75%, 80%, 90% or at least 95%, and most preferably, silencing or reduced expression of an essential gene results in the death of the diseased cell. Preferably, all copies of the essential gene found in the diseased cell have a disease-specific mutation.

[0016] Essential genes are well known in the art; for example, lists of essential genes in humans (e.g., in human cell lines or inferred from other organisms) are disclosed in Liao et al., 2008, Proc. Nat. Acad. Sci. USA 105: 6987-6992 and Georgi et al., 2013, PLoS Genetics 9 (5):e1003484, as well as essential genes in mouse (Liao et al., 2007, Trends Genet. 23:378-381), fruit fly (Spradling et al., 1999, Genetics 153:135-177), C. elegans (Kamath et al., 2003, Nature 421:231-237), zebrafish (Amsterdam et al., 2004, Proc. Natl. Acad. Corresponding orthologues in other eukaryotes have also been disclosed, such as Arabidopsis thaliana (Tzafrir et al., 2004, Plant Physiol. 135:1206-1220), yeast (Kim et al., 2010, Nat. Biotechnol. 28:617-623), etc. A list of essential genes from human cancer cell lines is disclosed in Wang et al., 2015, Science 350:1096-1101, and a list of essential genes can be found in the database of essential genes, DEG5.0 (Zhang et al., 2009, Nucleic Acids Res. 37:D455-D458).

[0017] Moreover, a list of essential genes whose deletion / silencing significantly reduces the fitness of a cohort of cell lines can be generated empirically from multiple healthy tissues and / or cancer cell lines, which can be derived from a donor or a patient. Gene deletion / silencing can be performed experimentally using various molecular biology techniques, such as CRISPR technology, RNA interference, etc., and cell survival or fitness is determined by the presence or absence of expression of the putative essential genes. The list of essential genes can also be determined experimentally from cells or cell lines, or the list of essential genes can be obtained by bioinformatics approaches. The cells or cell lines can be diseased cells or cell lines (tumor cells or cell lines) or non-diseased (healthy / normal) cells or cell lines, and can be obtained from a donor or a patient with the disease. Preferably, the non-diseased cells or cell lines are derived from the same tissue type as the diseased cells, and more preferably from the same patient. In embodiments where the disease is cancer, the cells or cell lines can be obtained from the primary tumor or any metastasis, if present. Furthermore, the list of essential genes can be essentially the same as the minimum set of genes expressed in a wide variety of tissues in the body. For example, essential genes are genes expressed in a wide variety of different tissues and expressed at a RPKM (minimum reads per kilobase of transcript per million mapped reads) threshold of more than 0, preferably more than 0.1, 0.5, 1, 2, 3, 4, 5, 10, 20, 25. Such a list of essential genes can be obtained by analyzing RNA expression data (e.g., RNAseq) from a panel of cell samples from at least 5, 6, 7, 8, 9, 10, 15, 20, 25 or more different tissues. Furthermore, if patient-derived tumor cell lines are available, genes in which all copies contain mutations encoding neoepitopes can be deleted one at a time and the growth rate of each modified cell line measured.Such measurements / analysis can be performed by high-throughput methods known in the art, which allow screening at least one gene at a time, preferably many genes at a time, to evaluate their effect on the fitness of diseased or non-diseased cells. Such methods also allow detection of synthetic diseased or lethal combinations of genes, as described below. Briefly, deletion of one or more candidate genes can be tested using a library of cell lines, each cell line lacking one gene, so that the effect of gene deletion on cells can be determined.

[0018] The present invention further relates to a method for determining the suitability of a neoepitope resulting from a disease-specific mutation in a gene as a disease-specific target, comprising determining the copy number of the gene in a diseased cell or a population of diseased cells, i.e. determining the copy number of the gene, at least one copy of which has a disease-specific mutation. If a gene has a high copy number in a diseased cell, such as a tumor cell, for example due to focal amplification, there is a high probability that the gene can be a driver gene. Thus, a high copy number of a gene indicates suitability as a disease-specific target of the neoepitope, the higher the copy number of the gene, the higher the suitability of the neoepitope as a disease-specific target. For example, a high copy number can be more than 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or even more than 100 copies. A high copy number can be at least 50% greater than the copy number of the gene in a corresponding non-diseased cell. A high copy number may be when the copy number of a gene, at least one copy of which has a disease-specific mutation, is at least 2x, 3x, 5x, 10x, 15x, 20x, 25x, 30x, 40x, 50x, 60x, 70x, 80x, 90x, or at least 100x greater than the copy number of the gene in a corresponding non-diseased cell. Due to copy number variation that may also be present in normal genomes, the copy number of a gene in a normal genome is not necessarily 2. Furthermore, focal amplifications are known to be observed more frequently in certain diseases than in other diseases, such as in glioblastoma, where the epidermal growth factor receptor gene is frequently focally amplified, and thus the present embodiment is well suited for use in these diseases.

[0019] Furthermore, it is preferred that the copy number of a gene is found to be the same or similar in a high percentage of diseased cells as opposed to a low percentage of diseased cells, such that the higher the percentage of diseased cells with the same or similar copy number, the more suitable the neoepitope is as a disease-specific target. In a preferred embodiment, all diseased cells in a diseased tissue have the same or similar copy number of a gene, at least one copy of which has a disease-specific mutation, i.e., a clonal proportion of 1. As used herein, the same or similar copy number encompasses the same copy number, or a copy number within 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or less of the copy number or absolute copy number, with or without error correction.

[0020] Furthermore, a gene with high copy number, at least one copy of which has a disease-specific mutation resulting in a neoepitope, may preferably be a gene whose expression leads to the transformation of a cell into a cancerous phenotype or whose lack of expression leads to a cancerous cell losing its cancerous phenotype, i.e. a driver gene, such as a driver gene known in the art, or may be an essential gene, e.g. a gene which, when silenced or whose expression is reduced, at least leads to impaired growth or reduced fitness of the affected cell.

[0021] The present invention also relates to a method for determining the suitability of a neoepitope resulting from a disease-specific mutation in a gene as a disease-specific target, comprising determining whether a gene with a disease-specific mutation is an essential gene in a diseased cell or a population of diseased cells. In one embodiment, an essential gene is a gene whose silenced or reduced expression (e.g., by deletion of the gene) at least leads to growth failure or reduced fitness of the diseased cell. In this embodiment, the suitability of the neoepitope as a preferred disease-specific target is indicated when the gene is an essential gene and all copies of the essential gene have a disease-specific mutation (a splicing ratio of 1). In an embodiment, an essential gene is a gene that is expressed in a wide variety of different tissues and is expressed at a RPKM (minimum reads per kilobase of transcript per million mapped reads) threshold of more than 0, preferably more than 0.1, 0.5, 1, 2, 3, 4, 5, 10, 20, 25. Preferably, all copies of the essential gene contain the mutation. Furthermore, it is preferred that a high proportion of diseased cells contain copies of the essential gene in all copies of which the disease-specific mutation is present (a high rather than a low clonal fraction), such that the higher the proportion of diseased cells that contain copies of the essential gene in all copies of which the disease-specific mutation is present, the more suitable they are as disease-specific targets for the neoepitope. In a more preferred embodiment, all diseased cells in the diseased tissue have the essential gene in all copies of which the disease-specific mutation is present, i.e., the clonal fraction is 1.

[0022] It is known that certain genes, when individually silenced or their expression is reduced, may have little, if any, effect on the fitness or growth potential of affected cells. However, it has been observed that two of such genes, when both silenced or each expression is reduced, can result in a much stronger growth impairment leading to lethality. Such genetic combinations are called synthetic lethal or synthetic disease / impaired. For a discussion of synthetic lethal and synthetic disease genes and methods for identifying such genes, see Nijman, 2011, Synthetic lethality: General principles, utility and detection using genetic screens in human cells, FEBS Lett. 585:1-6. Because both genes are required for cell survival, it is unlikely that a cell will silence or down-regulate both genes. Thus, a suitable combination of neoepitopes as a disease-specific target may result from disease-specific mutations in at least two genes, which together are synthetically lethal or synthetically diseased. In view of this, the present invention further relates to a method for determining the suitability of a combination of at least two neoepitopes resulting from disease-specific mutations in at least two genes as a combination of disease-specific targets, comprising a step of determining whether the combination of at least two genes, each carrying a disease-specific mutation, is a synthetic lethal or synthetic diseased gene. If the combination of at least two genes results in a synthetic lethal or synthetic diseased phenotype, this indicates that the resulting neoepitopes are a suitable combination of disease-specific targets. In a preferred embodiment, the synthetic diseased results in at least a better effect on cell growth / fitness than would be expected from the additive effect of deleting / under-expressing each gene individually. This approach is preferred when there are a large number of suitable neoepitopes, since the greater the number of neoepitopes, the greater the number of combinations that can be synthetically diseased or lethal.For example, 10 mutations correspond to 45 possible combinations, 100 mutations correspond to 4950 combinations, and 1000 mutations correspond to about 500,000 combinations. In certain embodiments, at least two genes each have a higher conjugation rate than is lower, preferably a conjugation rate of 1, and / or each have a higher clonal ratio than is lower, preferably a clonal ratio of 1, both in diseased cells and diseased tissues. As used herein, each neoepitope found in a suitable neoepitope combination is considered to be a suitable neoepitope for the purposes of the present invention.

[0023] As referred to herein, the copy number of a gene in either a diseased or non-diseased cell can be a relative copy number, but is preferably an absolute copy number, and more preferably an absolute copy number normalized to the ploidy, e.g., ploidy, i.e., genomic copy number, of the diseased cell. Even more preferably, the relative, absolute and normalized copy numbers are error corrected.

[0024] For example, when estimating the absolute copy number of a mutated allele or gene or its zygosity status, the estimation may be inaccurate and one would like to correct the absolute copy number to take into account error sources. In embodiments where next generation sequencing is used to obtain sequence information from genomes and exomes, error sources may include: bias in the estimated purity of samples of diseased tissue such as tumor samples, bias in the estimation parameters required to derive purity and / or absolute copy number, stochastic errors due to finite coverage of the sample being sequenced, limited detection power due to low purity, low clonal fraction, etc.

[0025] In an embodiment where the absolute copy number is determined using balanced heterozygous segments containing heterozygous SNPs, such as those disclosed in the International PCT Patent Application entitled "Tumor Modeling Based on Primary Balanced Heterozygous Segments," filed on even date herewith, the entire disclosure of which is incorporated herein by reference, errors in the absolute copy number of the segment can propagate to other estimation parameters, such as the absolute copy number of the mutated allele, e.g., SNVs encoding neoepitopes, the zygosity status of the mutated allele, clonal proportions, etc. Since such downstream estimation parameters have clinical significance for determining the suitability of neoepitopes as disease-specific targets for patients as described herein, it is desirable to correct the errors in the absolute copy number to obtain the most accurate value of the absolute copy number. Furthermore, it is beneficial to have the most accurate estimate of the absolute copy number and any parameters derived therefrom, since mutations encoding neoepitopes can be prioritized with respect to their suitability for inclusion in a vaccine given to a patient using the criteria described herein, and because a fractional zygosity of 1 is qualitatively better than a fractional zygosity of less than 1, especially if the gene containing the mutation is an essential gene.

[0026] In a preferred embodiment, the mutated allele, e.g., absolute copy number of the SNV and / or zygosity status of the SNV, can be error corrected. In an embodiment, the absolute copy number of the SNV is first error corrected, and then the zygosity status of the SNV is corrected to reflect the error corrected absolute copy number of the SNV. Once the absolute copy number of the SNV and / or the zygosity status of the SNV are error corrected, the estimate of the clonal proportion can also be corrected to reflect the error corrected absolute copy number, including a determination of whether the clonal proportion is statistically consistent with a value of 1.

[0027] The absolute copy number of SNV is preferably obtained by the absolute copy number of the segment to which SNV is mapped.The absolute copy number of all segments in disease, for example, tumor genome can be error-corrected, which includes the absolute copy number of SNV.After the absolute copy number of all segments in genome is error-corrected, error-corrected ploidy can be calculated based on the error-corrected absolute copy number of segments in disease, for example, tumor genome.

[0028] In a specific embodiment, if the absolute copy number of an SNV is error-corrected such that the new absolute copy number differs from the original absolute copy number, this can be interpreted as an indication that the estimated absolute copy number of the SNV is unreliable.

[0029] An example of segmental absolute copy number error correction is parity error correction, which involves correction of an odd absolute copy number of a segment to an even absolute copy number if the segment is in a balanced region, which is a region of the diseased, e.g., tumor genome, in which the maternal and paternal alleles have undergone equal (balanced) amplification, or both the maternal and paternal alleles have not undergone any amplification at all.

[0030] The decision to error-correct the odd absolute copy number of the segment to the nearest higher even absolute copy number or the nearest lower even absolute copy number can depend on the disease read data and normal read data mapped to the segment, and the comparison to the predicted boundary that defines the absolute copy number of the segment.When the normal read data is the read data related to the sequenced normal sample, the disease read data is the read data related to the sequenced diseased sample.In particular, when the disease is cancer, the tumor read data is the read data related to the sequenced tumor sample.

[0031] For example, in the first type of parity error correction, CN mutIf CN is the absolute copy number in the affected genome of the segment to which the mutation maps, then mut The absolute copy number of a segment predicted to have a value of r>ρ th If so, CN mut +1, and r<ρ th If so, CN mut −1, r is the disease to normal segment read count ratio (the ratio of the number of disease, e.g., tumor reads mapping to the segment to the number of normal reads mapping to the segment), and ρ th is the predicted decision boundary, the value of which also depends on the purity of the diseased tissue sample, e.g., the tumor sample.

[0032] The allele-specific copy number of a segment is the number of copies in the affected genome of either the maternal or paternal allele of the segment. If a segment contains heterozygous SNPs (heterozygous segments), the heterozygous SNPs can be used to determine the allele-specific copy number of the segment. Heterozygous segments can be assigned to preferred nodes, and a node can be defined as a unique combination of the absolute copy number of the heterozygous segment and the allele-specific copy number of the heterozygous segment. An even node is a subset of nodes in which the absolute copy number of the segment is even. If a heterozygous segment contains more than one heterozygous SNP, a group of two or more heterozygous SNPs may be represented by a single member of the group, or the allele frequencies of all members of the group may be averaged, or the median value may be taken, as long as the allele frequency of each heterozygous SNP is calculated consistently for either the allele with more or less copies in the affected genome.

[0033] A first type of parity error correction for heterozygous segments may involve, for example, finding the even node that is most likely to correspond to the heterozygous segment based on a maximum likelihood framework that takes into account the measured disease (e.g., tumor) read data and normal read data that are mapped to the segment.

[0034] In the second type of parity error correction, the nearest upstream and downstream segments that do not require parity error correction are preferably identified within 10Mb, 5Mb, 1Mb of the segment containing SNV.If the absolute copy number of both the nearest upstream and downstream segments is the same, the absolute copy number of the segment containing SNV is changed to the absolute copy number of the nearest segment.In general, the second type of parity error correction is preferred to the first type of parity error correction, except when it cannot be performed due to the inability to identify suitable adjacent segments, in which case the first type of parity error correction can be provided.

[0035] Instead of or in addition to parity error correction, other forms of error correction of absolute copy number of segments can also be introduced, such as a method that considers the absolute copy number of the segment in the immediate vicinity of the gene containing the mutation in the affected genome, preferably when the absolute copy number change is less than 3, 2, preferably 1, and preferably when the majority of the neighboring segments (50%, 60%, 70%, 80%, 90%, 100%) have an absolute copy number similar to the mode, the absolute copy number of the segment containing the SNV is changed to the mode of the absolute copy number of the neighboring segments.

[0036] Different error correction schemes for absolute copy number can be combined. In a preferred embodiment, a first parity error correction is applied as a first layer of error correction, on top of which additional error correction methods can be applied.

[0037] As used herein, a segment can be a predefined genomic region, e.g., predefined based on a reference genome. A segment can span, for example, a gene defined in a reference genome to which read data is aligned. A segment can be a fragment of a gene, an exon, a union of exons, or a union of exons associated with a given gene. A segment can be another set of predefined regions in a reference genome (with or without introns), or another set of predefined regions in a reference genome based on a normal genome. In a specific embodiment, a segment can be a region of a reference genome with a given constant copy number and / or a given allele-specific copy number in a diseased, e.g., tumor genome, or a fragment of a gene with a given constant copy number and / or an allele-specific copy number in a diseased, e.g., tumor genome. A segment can be defined as including or excluding introns.

[0038] The number of copies of a segment in a given genome (e.g., a normal genome or a tumor genome) can be defined as the frequency with which the nucleotide sequence of the segment occurs in the genome in total, ignoring the variation due to SNPs and / or SNVs and / or other cancer-related alterations, including but not limited to mutations, insertions, deletions and / or other cancer-related genetic variants, etc. Preferably, the different copies of a segment in a given genome have the same or approximately the same length.

[0039] The number of copies of a segment in a genome can refer to the number of physical copies of the segment in a cell that contains the genome. The absolute copy number of a segment in a normal genome can be defined as the number of physical copies of a given segment in a healthy cell. The absolute copy number of a segment in a diseased, e.g., tumor genome can be defined as the number of physical copies of a given segment in a diseased, e.g., tumor cell. The number of copies of a segment in a genome can be referred to as the absolute copy number of the segment in said genome. Copy number can refer to absolute copy number.

[0040] In specific embodiments, if only a portion of a segment is amplified or deleted in a genome, such partial copies of the segment may or may not be counted as copies of the segment. In preferred embodiments, copies of the segment that span less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% of the segment length may be disregarded.

[0041] The reference genome is used to map the read data and provide a coordinate system for the normal and diseased, e.g., tumor, genomes, which may include providing the chromosome number, the nucleotide position in the chromosome, and the directionality of the read data, with the position in the chromosome indicated by a line.

[0042] The reference genome can be based on the genome of one or more members from the same species as the subject providing the sample of diseased tissue, or can be based on the normal genome of the subject.

[0043] A sample of diseased tissue, such as a tumor sample, may also contain contamination from normal genomes, in particular from the normal genome of the same patient from which the sample was taken, and / or more than one tumor genome in the case of intratumoral heterogeneity. Purity, tumor sample purity, tumor purity and sample purity are all taken to be equivalent terms and preferably refer to the proportion of tumor cells present in the tumor sample. Normal contamination preferably refers to the proportion of normal cells present in the tumor sample and can be obtained by 1 minus purity.

[0044] Normalization to the ploidy of a cell controls for the presence of copies of a gene due to genome duplication events.In an embodiment, absolute copy number can be normalized to the ploidy of genome, which is the average of the absolute copy number of all segments in a given genome in a given cell, weighted by the length of each segment.In an embodiment, absolute copy number can be normalized to the ploidy of the chromosome containing the mutated gene of interest (including mutation), which is the average of the absolute copy number of all segments on a given chromosome in a given cell, weighted by the length of each segment on the chromosome.In an embodiment, absolute copy number can be normalized to the ploidy of the adjacent region of the chromosome containing the mutated gene of interest, which is the average of each segment in a given region in a given cell, weighted by the length of each segment in the region. The flanking region can be within a predetermined distance of the gene having a disease-specific mutation, for example, within 100 megabases (Mb), 75 Mb, 50 Mb, 25 Mb, 10 Mb, 5 Mb, 4 Mb, 3 Mb, 2 Mb, or 1 Mb of the gene having a disease-specific mutation. The copy number of a segment can be routinely calculated by methods known in the art, both experimentally and computationally. For example, European Patent No. 2 198 292 (B1) and European Patent No. 2 002 016 (B1) disclose methods for determining the relative copy number and copy number frequency of a nucleic acid sequence, respectively. In addition, European Patent Application Publication No. 2 835 752 (A) and International Patent Application Publication Nos. WO 2014 / 014497 and WO 2014 / 138153 also disclose methods for determining copy number diversity. See also Machado et al., 2013, Copy Number Variation of Fc Gamma Receptor Genes in HIV-Infected and HIV-Tuberculosis Co-Infected Individuals in Sub-Saharan Africa, PLoS, 8(11):e78165. Other methods include the use of FACS, FISH or other fluorescence-based methods, spectral karyotyping (SKY) and digital PCR.The segment may be a gene.

[0045] The disease-specific mutation may be any mutation that leads to the expression of a neo-epitope on the surface of the diseased cell. In particular, the mutation may be an indel or gene fusion event, or may be a single base variation (point mutation). Preferably, the disease-specific mutation is a non-synonymous mutation, preferably a non-synonymous mutation of a protein expressed in tumor or cancer cells. Any method known in the art for determining disease-specific mutations may be used, and in particular, a method that uses next generation sequencing data to determine any changes between the genome / exome of diseased cells compared to the genome / exome of the corresponding non-diseased wild-type cell is preferred. For example, Carter et al., 2012, Absolute quantification of somatic DNA alterations in human cancer, Nature Biotechnology 30:413-421; Cibulskis et al., 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nature Biotechnology 31:213-219; and Li and Li, 2014, A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data, Genome Biology 15:473-495 disclose methods for identifying disease-specific mutations, as well as determining the relative subclonality and zygosity rates of gene copy numbers, zygosity rates and zygosity status.Another method for determining copy number, such as absolute copy number, involves the use of segments of a genome, each segment containing at least one heterozygous single nucleotide polymorphism (SNP), which are balanced (equal number of heterozygous SNPs in each version) and share a common number of copies (primary copy number), which is preferably the most frequently observed absolute copy number of all balanced segments of the genome, as disclosed in the International PCT Patent Application entitled "Tumor Modeling Based on Primary Balanced Heterozygous Segments", filed on even date herewith, the disclosure of which is incorporated herein by reference in its entirety. Furthermore, in addition to determining absolute copy number, the present application can also determine the zygosity status, zygosity rate and subclonality of genes that contain mutated alleles or at least one copy of mutated alleles. Furthermore, the methodology therein also performs error correction on the absolute copy number, which improves the accuracy of the absolute copy number and zygosity status and parameters derived therefrom, such as subclonality, ploidy, etc.

[0046] Generally, the total number of copies of the nucleotide site where the mutated allele is mapped can refer to the absolute copy number of the mutation, and this can refer to the absolute copy number of the SNV, particularly when the mutation is an SNV.Generally, the absolute copy number of the mutation can be preferably obtained by the absolute copy number of the segment where the mutation is mapped (the absolute copy number is in the affected, for example, tumor genome).

[0047] In general, the copy number of a mutated allele encoding a neoepitope can refer to the absolute copy number of the mutated allele of the mutation, which can refer to the absolute copy number of the alternative allele of the SNV (the zygosity state of the SNV), in particular, when the mutation is an SNV, the alternative allele of the SNV is the mutated allele.

[0048] Preferably, when the mutation is not an SNV, the absolute copy number of the mutated allele of the mutation can be estimated in a similar manner as applied to SNVs.

[0049] In general, the copy number of a gene can refer to the absolute copy number of a segment, where a segment can be or include a gene. The copy number of a gene can refer to the absolute copy number of the gene.

[0050] Preferably, the disease may be any disease in which an immune response against diseased cells / tissues is desired, such as virally infected cells, etc. Preferably, the disease is cancer.

[0051] The method of the invention may include further steps of determining the utility / relevance of a suitable neoepitope identified by the method of the invention as a disease-specific target suitable for use in a method for generating an immune response against the suitable neoepitope, such as inclusion of the suitable neoepitope in a cancer vaccine. Thus, the further steps may involve one or more of the following: determining the antigenicity and / or immunogenicity of the suitable neoepitope; assessing whether the suitable neoepitope is expressed on the surface of diseased cells; the ability of a peptide comprising the suitable neoepitope to be presented as an MHC-presented epitope; determining the effectiveness of expression of the suitable neoepitope from an encoding nucleic acid; determining whether the putative suitable neoepitope, especially when present in the context of its native sequence, e.g. flanked by amino acid sequences flanking said neoepitope in a naturally occurring protein as well as when expressed in antigen-presenting cells, is capable of stimulating T cells, such as T cells of a patient with the desired specificity.

[0052] Once it has been determined that a neoepitope is suitable / appropriate for use as a target, taking into account its antigenicity / immunogenicity, ability to be expressed, ability to be presented as an MHC-presented epitope, etc., suitable neoepitopes identified can be ranked, i.e., prioritized, in terms of their potential to not be downregulated or deleted from diseased cells, which potential makes it unlikely that diseased tissues will be able to avoid targeting of the neoepitope. For example, one prioritization might start with the "best" neoepitope, which is a neoepitope encoded by an essential gene, where all copies of the essential gene have a mutation that codes for the neoepitope, then a pair of synthetic diseased or lethal genes, where each copy of each gene has a mutation that codes for the neoepitope, then a neoepitope encoded by a known driver gene with very high absolute copy number, where all copies of this gene have mutations, then a neoepitope encoded by a gene not known to be a driver gene, with very high absolute copy number and high zygosity, then a neoepitope encoded by a gene with high copy number (zygosity state), and so on.

[0053] In an embodiment, a neoepitope encoded by an essential gene with a splicing ratio of 1 is preferred over other neoepitopes not encoded by essential genes. In an embodiment, between two essential genes encoding neoepitopes with a splicing ratio of 1, a neoepitope encoded by a gene with a higher absolute copy number is preferred. In an embodiment, between two essential genes encoding neoepitopes, a neoepitope encoded by a gene that, when deleted, results in lower fitness is preferred. In an embodiment, between genes encoding neoepitopes where all genes have a splicing ratio of 1, a neoepitope encoded by a gene with a higher absolute copy number is preferred. In an embodiment, when the zygosity rate is less than 1, neoepitopes encoded by genes with high zygosity are preferred over genes with high zygosity rate, and when the zygosity rate is the same or similar, genes with high absolute copy number are preferred over genes with high zygosity rate (10 copies of mutated allele / 20 total copies of nucleotide site is better than 3 / 4 due to higher zygosity; 10 / 100 is better than 10 / 20 because the former may be a driver gene; 9 / 100 is better than 10 / 20 because the former may be a driver gene, although the zygosity rate is similar). In an embodiment, neoepitopes encoded by driver genes whose disease-specific mutations are responsible for the transformation of cells to a cancerous phenotype are preferred over those whose mutations have no role in the transformation of cells to a cancerous phenotype. Furthermore, it is preferred that neoepitopes have a higher clonal fraction rather than a lower one.

[0054] A further embodiment of the present invention relates to the use of the method to determine the suitability of a neoepitope as a disease-specific target for the production of a vaccine, e.g. a medicament, such as a personalized cancer vaccine. The vaccine can be derived from one or more suitable neoepitopes or a combination of suitable neoepitopes identified by the method of the present invention. In a preferred embodiment, the vaccine comprises a peptide or polypeptide comprising one or more suitable neoepitopes or a combination of suitable neoepitopes identified by the method of the present invention, or a nucleic acid encoding said peptide or polypeptide.

[0055] In particular, recombinant vaccines can be provided which, when administered to a patient, preferably result in a collection of MHC-presented epitopes, at least one of which is a suitable neoepitope, or at least two of which are suitable combinations of neoepitopes identified by the methods of the invention, such as 2 or more, 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, preferably up to 60, up to 55, up to 50, up to 45, up to 40, up to 35 or up to 30 MHC-presented epitopes. Presentation of these epitopes by the patient's cells, in particular antigen-presenting cells, preferably results in T cells targeting the patient's tumor, preferably primary tumor and tumor metastases, which express the epitope when bound to MHC and thus the antigen from which the MHC-presented epitope is derived, and presenting the same on the surface of the tumor cells.

[0056] The methods of the invention are also useful in the production of recombinant immune cells expressing an antigen receptor targeted to a suitable neoepitope, or to one of a combination of suitable neoepitopes. Preferably, the immune cell is a T cell and the antigen receptor is a T cell receptor.

[0057] The present invention also relates to a method for producing recombinant immune cells targeted to a suitable neoepitope, or to one epitope in a combination of suitable neoepitopes, comprising the step of transfecting an immune cell with a recombinant antigen receptor targeted to a suitable neoepitope, or to one epitope in a combination of suitable epitopes, identified by the method of the present invention for determining the suitability of a neoepitope as a disease-specific target, as well as to recombinant immune cells produced by such a method.

[0058] The present invention also provides methods for targeting cell populations or tissues expressing one or more neoepitopes. For example, antibodies against one or more of the neoepitopes can be used to target cells or tissues expressing one or more neoepitopes identified by the methods described herein. In one embodiment, the present invention provides a method for generating an immune response against a target cell population or tissue expressing one or more neoepitopes in a mammal, comprising the steps of: (a) administering to the mammal one or more immune cells expressing one or more antigen receptors targeted to one or more neoepitopes; (b) administering a nucleic acid encoding one or more of the neoepitopes; or (c) administering a peptide or polypeptide comprising one or more of the neoepitopes, wherein the neoepitopes are identified according to the methods of the present invention for determining the suitability of the neoepitopes as disease-specific targets. In one embodiment, a method for generating an immune response against a target cell population or target tissue expressing one or more neoepitopes in a mammal comprises: (i) determining the copy number of a mutated allele in a gene encoding the neoepitopes (disease-specific mutations) in a diseased cell or diseased cell population; and (ii) (a) administering an immune cell expressing an antigen receptor targeted to the neoepitope resulting from the disease-specific mutation; (b) administering a nucleic acid encoding the neoepitope resulting from the disease-specific mutation; or (c) administering a peptide or polypeptide comprising the neoepitope resulting from the disease-specific mutation.

[0059] In one embodiment, a method for generating an immune response against a target cell population or target tissue expressing one or more neoepitopes in a mammal comprises: (i) determining the copy number of a gene in a diseased cell or diseased cell population, where at least one copy of the gene has a disease-specific mutation that results in the neoepitope; and (ii) (a) administering an immune cell expressing an antigen receptor targeted to the neoepitope resulting from the disease-specific mutation; (b) administering a nucleic acid encoding the neoepitope resulting from the disease-specific mutation; or (c) administering a peptide or polypeptide that includes the neoepitope resulting from the disease-specific mutation. In one embodiment, a method for generating an immune response against a target cell population or target tissue expressing one or more neoepitopes in a mammal comprises the steps of: (i) determining whether a gene having a disease-specific mutation resulting in the neoepitopes is an essential gene in a diseased cell or diseased cell population; and (ii) (a) administering an immune cell expressing an antigen receptor targeted to the neoepitope resulting from the disease-specific mutation; (b) administering a nucleic acid encoding the neoepitope resulting from the disease-specific mutation; or (c) administering a peptide or polypeptide comprising the neoepitope resulting from the disease-specific mutation. Preferably, all copies of the essential gene have the disease-specific mutation, i.e., the splicing ratio is 1.

[0060] In one embodiment, a method for generating an immune response against a target cell population or target tissue expressing one or more neoepitopes in a mammal comprises the steps of: (i) determining in a diseased cell or diseased cell population whether a combination of at least two genes, each having a disease-specific mutation resulting in a neoepitope, is a synthetic lethal or synthetic disease gene; and (ii) (a) administering one or more immune cells expressing one or more antigen receptors targeted to one or more neoepitopes resulting from a disease-specific mutation in at least two genes; (b) administering a nucleic acid encoding one or more neoepitopes resulting from a disease-specific mutation in at least two genes; or (c) administering a peptide or polypeptide comprising one or more neoepitopes resulting from a disease-specific mutation in at least two genes. Preferably, all neoepitopes resulting from a disease-specific mutation in at least two genes are targeted by the administered immune cells, encoded by the administered nucleic acid, or contained within the administered peptide or polypeptide.

[0061] Furthermore, an immune response can be generated in a mammal having a disease, disorder or condition associated with expression of a neoepitope resulting from a disease-specific mutation, such that the disease, disorder or condition can be treated or prevented. Preferably, the disease, disorder or condition is cancer.

[0062] Preferably, the immune cells are T cells, the antigen receptor is a T cell receptor and the immune response is a T cell mediated immune response. More preferably, the immune response is an anti-tumor immune response and the target cell population or target tissue expressing one or more suitable neoepitopes is a tumor cell or tumor tissue.

[0063] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0064] The present invention is described in detail below, but it should be understood that the present invention is not limited to the specific methods, protocols, and reagents described herein, since the methods, protocols, and reagents may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0065] The elements of the present invention are described below. Although these elements are described with specific embodiments, it is understood that they may be combined in any manner and in any number to create additional embodiments. The various described preferred embodiments should not be construed as limiting the invention to only the explicitly described embodiments. This description should be understood to support and encompass embodiments combining the explicitly described embodiments with any number of the disclosed and / or preferred elements. Furthermore, unless otherwise indicated by the content, any permutation and combination of all described elements in this application should be considered as disclosed by the description of this application. For example, in a preferred embodiment, if the neoepitope has a high junction state rather than a high junction rate, and in a preferred embodiment, the neoepitope is due to a mutation in an essential gene, in a preferred embodiment, a suitable neoepitope has a high junction rate and is due to a mutation in an essential gene, and in a more preferred embodiment, the junction rate is equal to 1.

[0066] Preferably, the terms used herein are defined as set forth in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", edited by HGW Leuenberger, B. Nagel, and H. Kolbl, (1995) Helvetica Chimica Acta, CH-4010, Basel, Switzerland.

[0067] Unless otherwise indicated, the practice of the present invention employs conventional methods of biochemistry, cell biology, immunology, and recombinant DNA techniques as described in the art (see, e.g., Molecular Cloning: A Laboratory Manual, 2nd Edition, edited by J. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).

[0068] Unless otherwise required by context, throughout this specification and the claims that follow, the word "comprise" and variations such as "comprises" and "comprising" are to be understood as implying the inclusion of a stated member, integer or step, or group of members, integers or steps, but not the exclusion of any other members, integers or steps, or group of members, integers or steps, although in some embodiments, such other members, integers or steps, or group of members, integers or steps may be excluded, i.e., the subject matter consists of the inclusion of a stated member, integer or step, or group of members, integers or steps. The terms "a" and "an" and "the" and similar references used in the context of the description of the invention (particularly in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise specified herein or clearly contradicted by context. Recitation of ranges of values ​​herein is intended only to serve as a shorthand method of referring individually to each separate value within the range. Unless otherwise stated herein, each individual value is incorporated herein as if it were individually listed herein.

[0069] All methods described herein can be performed in any suitable order unless otherwise specified herein or clearly contradicted by the context. For example, determining whether a neoepitope is a suitable disease-specific target by determining the copy number of the encoding gene can be determined before, after, or simultaneously with determining that the gene is a driver gene or an essential gene, or determining that the neoepitope is expressed on the surface of a cell or induces a good immune response such that it is suitable in a vaccine.

[0070] The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the invention and does not pose a limitation on the scope of the invention as claimed elsewhere. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[0071] Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, is incorporated herein by reference in its entirety. Nothing herein should be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0072] The present invention contemplates treatment of diseases, including immunotherapy and radiotherapy in certain cancers, by targeting neoepitopes that have the characteristic of being expressed from genes that are only expressed inside or on the surface of diseased cells and are unlikely to be silenced by diseased cells, such that the diseased cells are unlikely to be able to evade immune surveillance by the targeted neoepitopes ("suitable neoepitopes"). Immunotherapy can be provided by active and / or passive immunotherapy methods. For example, in one embodiment, antibodies or other molecules that specifically target the neoepitopes and are conjugated to toxic agents capable of killing cells expressing the neoepitopes can be used in accordance with the present invention to target and kill the cells.

[0073] The present invention is particularly directed to the identification of such suitable neoepitopes as disease-specific targets in immunotherapy. Once a suitable neoepitope has been identified, it can be used in a vaccine to induce an immune response against the neoepitope by inducing and / or activating suitable effector cells, such as T cells, that recognize the identified suitable neoepitope, particularly when presented in the context of MHC, via a suitable antigen receptor, such as a T cell receptor or an artificial T cell receptor, which will result in the death of diseased cells expressing the suitable neoepitope. Alternatively or additionally, immune cells that recognize the identified suitable neoepitope, via a suitable antigen receptor, can be administered, which will also result in the death of cells expressing the suitable neoepitope.

[0074] Immunotherapeutic approaches according to the invention include immunization with a suitable neoepitope-containing peptide or polypeptide, ii) a nucleic acid encoding the suitable neoepitope-containing peptide or polypeptide, iii) a recombinant cell encoding the suitable neoepitope-containing peptide or polypeptide, iv) a recombinant virus encoding the neoepitope-containing peptide or polypeptide, and v) an antigen-presenting cell pulsed with the neoepitope-containing peptide or polypeptide or transfected with a nucleic acid encoding the peptide or polypeptide. Other immunotherapeutic approaches according to the invention include vi) a T cell receptor that recognizes the neoepitope, and vii) the transfer of an effector cell (such as a T cell) that encodes a receptor that recognizes the neoepitope, particularly when presented in the context of the MHC.

[0075] The term "disease-specific mutation" in the context of the present invention relates to a somatic mutation that is present in the nucleic acid of a diseased cell but not present in the nucleic acid of a corresponding normal, non-diseased cell. Since the disease may be cancer, the term "tumor-specific mutation" or "cancer-specific mutation" relates to a somatic mutation that is present in the nucleic acid of a tumor or cancer cell but not present in the nucleic acid of a corresponding normal, i.e. non-neoplastic or non-cancerous cell. The terms "tumor-specific mutation" and "tumor mutation" and the terms "cancer-specific mutation" and "cancer mutation" are used interchangeably herein.

[0076] As used herein, a single nucleotide polymorphism (SNP) is a site in the normal genome where at least one of the two alleles (maternal or paternal) has a different identity than in the normal genome or, for example, relative to a reference genome.

[0077] As used herein, a heterozygous single nucleotide polymorphism (heterozygous SNP) is defined as a site in the normal genome where two alleles (maternal and paternal alleles) have different identities.

[0078] As used herein, the term "junction rate" refers to the ratio of the copy number of a gene with a disease-specific mutation, taking into account the total copy number of the gene, whether the gene has a mutation or not. For example, if there are a total of 20 copies of a gene, and 10 of the copies have a disease-specific mutation, the junction rate is 0.5. If all copies of a gene have a disease-specific mutation, the junction rate is 1. The junction rate can be at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or at least 0.95. In the context of the present invention, a higher junction rate is preferred over a lower junction rate. In an embodiment, the junction rate of a mutated allele encoding an epitope, preferably a neoepitope, is the ratio of the copy number of the mutated allele to the total number of copies of the nucleotide site to which the mutated allele is mapped, for example in a reference genome.

[0079] As used herein, the term "clonal ratio" refers to the ratio of the number of diseased cells that contain the same disease-specific mutation in the same gene and its genetic characteristics, such as copy number and zygosity ratio, taking into account the total number of diseased cells, regardless of whether the diseased cells have the same mutation in the same gene. The term can also be applied to tumor tissue, in that the clonal ratio is the ratio of diseased cells in tumor tissue that contain the same disease-specific mutation in the same gene and its genetic characteristics, such as copy number, taking into account the total number of cells in the tumor tissue. For example, in a sample obtained from a tumor in which only half of the total number of tumor cells have the same mutation in the same gene, the clonal ratio is 0.5. The clonal ratio can be at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or at least 0.95. In the context of the present invention, a higher clonal ratio is preferred over a lower clonal ratio. A clonal ratio of 1 is most preferred, in which all diseased cells have the same disease-specific mutation in the same gene. "Clonal proportion," "proportional clonality," and "proportional subclonality" are used interchangeably herein.

[0080] The term "focal amplification" refers to the amplification or copy number increase of a portion of the genome, for example, amplification of one or more genes co-located on the same chromosome, which results in a copy number of more than 2, preferably more than 5, 10, 15, 20, 25, 50, 75, 100, for that portion of the genome in the absence of a deletion event for that portion of the genome. Thus, for the purposes of the present invention, a gene that is focally amplified in a diseased cell is one that may have an increased copy number compared to a wild-type copy number of 2, or in the case of that gene on the X and Y chromosomes in males, a wild-type copy number of 1. Focal amplification is distinct from whole genome duplication and / or amplification events.

[0081] The term "immune response" refers to the integrated bodily response to an antigen, preferably a cellular immune response or a cellular and humoral immune response. The immune response can be protective, preventative / prophylactic and / or therapeutic.

[0082] "Induction of an immune response" can mean that there was no immune response against a particular antigen before induction, but it can also mean that there was a level of immune response against a particular antigen before induction, and that the immune response was enhanced after induction. Thus, "inducing an immune response" also includes "enhancing an immune response". Preferably, after inducing an immune response in a subject, the subject is protected from developing a disease, such as a cancer disease, or the disease condition is ameliorated by inducing an immune response. For example, an immune response against a tumor-expressed antigen can be induced in a patient suffering from a cancer disease or a subject at risk of developing a cancer disease. In this case, inducing an immune response can mean that the disease condition of the subject is ameliorated, the subject does not develop metastasis, or a subject at risk of developing a cancer disease does not develop a cancer disease.

[0083] "Cellular immune response", "cellular response", "cellular response to antigen" or similar terms are meant to include a cellular response to cells characterized by the presentation of antigen with class I or class II MHC. Cellular responses involve cells called T cells or T lymphocytes that act as either "helpers" or "killers". Helper T cells (CD4 + T cells (also called CD8 T cells) play a central role by regulating the immune response and are involved in the production of killer cells (cytotoxic T cells, cytolytic T cells, CD8 + Anti-tumor CTL responses (also called T cells or CTLs) kill diseased cells, such as cancer cells, and prevent the production of further diseased cells. Preferably, anti-tumor CTL responses are stimulated against tumor cells that express one or more tumor-expressed antigens, and preferably present the tumor-expressed antigens with class I MHC.

[0084] An "antigen" according to the present invention covers any substance, preferably a peptide or protein, that is the target of and / or induces an immune response, such as a specific reaction with an antibody or T lymphocyte (T cell). Preferably, the antigen comprises at least one epitope, such as a T cell epitope. Preferably, the antigen in the context of the invention is a molecule that induces an immune response, optionally after processing, that is preferably specific to the antigen (including cells expressing the antigen). The antigen or its T cell epitope is presented, preferably by cells, preferably antigen presenting cells, including diseased cells, in particular cancer cells, in the context of an MHC molecule that results in an immune response against the antigen (including cells expressing the antigen).

[0085] Preferably, an antigen in the context of the present invention is a molecule that induces an immune response, preferably specific to the antigen, optionally after processing. According to the present invention, any suitable antigen that is a candidate for an immune response can be used, the immune response being both a humoral and a cellular immune response. In the context of the present invention, the antigen is preferably presented by a cell, preferably an antigen-presenting cell, in the context of an MHC molecule, which results in an immune response against the antigen. The antigen is preferably a product corresponding to or derived from an antigen of natural origin. Such antigens of natural origin can include or be derived from allergens, viruses, bacteria, fungi, parasites and other infectious agents and pathogens, or the antigen may be a tumor antigen. According to the present invention, the antigen can correspond to a product of natural origin, for example a viral protein or part thereof. In a preferred embodiment, the antigen is a surface polypeptide, i.e. a polypeptide that is naturally displayed on the surface of a cell, a pathogen, a bacterium, a virus, a fungus, a parasite, an allergen or a tumor. An antigen can elicit an immune response against a cell, a pathogen, a bacterium, a virus, a fungus, a parasite, an allergen, or a tumor.

[0086] The term "disease-associated antigen" or "disease-specific antigen" is used in its broadest sense to refer to any antigen associated with or specific for a disease. Such antigens are molecules containing epitopes that will stimulate the host's immune system to generate a cellular antigen-specific immune response and / or a humoral antibody response against the disease. Thus, disease-associated antigens can be used for therapeutic purposes. Disease-associated antigens are preferably associated with infection by a microorganism, typically a microbial antigen, or associated with cancer, typically a tumor.

[0087] The term "pathogen" refers to a pathogenic biological material capable of causing disease in an organism, preferably a vertebrate organism. Pathogens include microorganisms such as bacteria, unicellular eukaryotes (protozoa), fungi, as well as viruses.

[0088] In the context of the present invention, the term "tumor antigen" or "tumor-associated antigen" relates to a protein which is specifically expressed under normal conditions in a limited number of tissues and / or organs or at a specific developmental stage, for example a tumor antigen may be specifically expressed under normal conditions in gastric tissue, preferably gastric mucosa, reproductive organs, e.g. testis, trophoblastic tissue, e.g. placenta or germline cells, and is expressed or aberrantly expressed in one or more tumor or cancer tissues. In this context, a "limited number" preferably means not more than three, more preferably not more than two. In the context of the present invention, tumor antigens include, for example, differentiation antigens, preferably cell type-specific differentiation antigens, i.e. proteins which are specifically expressed under normal conditions in a particular cell type at a particular differentiation stage, cancer / testis antigens, i.e. proteins which are specifically expressed under normal conditions in the testis and possibly in the placenta, as well as germline-specific antigens. In the context of the present invention, tumor antigens are preferably associated with the cell surface of cancer cells and are preferably not or only rarely expressed in normal tissues. Preferably, tumor antigens or aberrant expression of tumor antigens identifies cancer cells. In the context of the present invention, the tumor antigen expressed by cancer cells in a subject, for example a patient suffering from cancer disease, is preferably a self-protein in said subject.In a preferred embodiment, the tumor antigen in the context of the present invention is specifically expressed in tissues or organs that are non-essential under normal conditions, i.e. tissues or organs that do not cause the death of the subject when damaged by the immune system, or in organs or structures of the body that are not accessible or only poorly accessible by the immune system.Preferably, the amino acid sequence of the tumor antigen is identical between the tumor antigen expressed in normal tissues and the tumor antigen expressed in cancer tissues.

[0089] According to the present invention, the terms "tumor antigen", "tumor-expressed antigen", "cancer antigen" and "antigen expressed in cancer" are equivalent and are used interchangeably herein.

[0090] The terms "epitope", "antigenic peptide", "antigenic epitope", "immunogenic peptide" and "MHC binding peptide" are used interchangeably herein and refer to an antigenic determinant on a molecule such as an antigen, i.e., a part or fragment of an immunologically active compound that is recognized by the immune system, e.g., by T cells, particularly when presented in the context of an MHC molecule. An epitope of a protein preferably comprises a continuous or discontinuous portion of said protein and is preferably 5-100, preferably 5-50, more preferably 8-30, most preferably 10-25 amino acids in length. For example, an epitope may be preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids in length. According to the present invention, an epitope may be an "MHC binding peptide" or an "antigenic peptide" since it is capable of binding to an MHC molecule, such as an MHC molecule on the surface of a cell. The term "major histocompatibility complex" and the abbreviation "MHC" refer to a complex of genes that includes MHC class I and MHC class II molecules and is present in all vertebrates. MHC proteins or molecules are important in signaling between lymphocytes and antigen presenting cells or diseased cells in an immune response, and MHC proteins or molecules bind peptides and present them for recognition by T cell receptors. Proteins encoded by MHC are expressed on the surface of cells and display both self antigens (peptide fragments from the cell itself) and non-self antigens (e.g. fragments of invading microorganisms) to T cells. Preferred such immunogenic moieties bind to MHC class I or class II molecules. As used herein, an immunogenic moiety is said to "bind" to an MHC class I or class II molecule if the binding is detectable using any assay known in the art. The term "MHC binding peptide" refers to a peptide that binds to an MHC class I and / or MHC class II molecule. For class I MHC / peptide complexes, the binding peptides are typically 8-10 amino acids in length, although longer or shorter peptides may be effective.For class II MHC / peptide complexes, the binding peptides are typically 10-25 amino acids in length, particularly 13-18 amino acids in length, although longer and shorter peptides may be effective.

[0091] As used herein, the term "neoepitope" refers to an epitope that is not present in a reference, such as a normal non-cancerous or germline cell, but is found in a diseased cell, such as a cancer cell. This specifically includes situations where a corresponding epitope is found in a normal non-cancerous or germline cell, but where one or more mutations in the cancer cell cause the sequence of the epitope to change, thereby creating a neoepitope. Furthermore, the neoepitope may not only be specific to the diseased cell, but also to the patient with the disease. Since the neoepitopes and suitable neoepitopes identified by the methods of the present invention are a subset of epitopes, the disclosures herein regarding epitopes as immunological targets in general apply equally to neoepitopes and suitable neoepitopes.

[0092] In a particularly preferred embodiment of the present invention, the epitope or neoepitope is a T cell epitope. As used herein, the term "T cell epitope" refers to a peptide that binds to an MHC molecule in a configuration that is recognized by a T cell receptor. Typically, T cell epitopes are presented on the surface of antigen-presenting cells.

[0093] As used herein, the term "prediction of an immunogenic amino acid modification" refers to a prediction as to whether a peptide containing such an amino acid modification will be immunogenic in vaccination and therefore useful as an epitope, in particular a T cell epitope.

[0094] According to the invention, a T cell epitope can be present in the vaccine as part of a larger entity, such as a vaccine sequence and / or polypeptide comprising two or more T cell epitopes. The presented peptides or T cell epitopes are produced after suitable processing.

[0095] T cell epitopes can be modified at one or more residues that are not essential for TCR recognition or binding to MHC and such modified T cell epitopes can be considered immunologically equivalent.

[0096] Preferably, the T cell epitope is presented by the MHC and, when recognized by a T cell receptor, is capable of inducing, in the presence of an appropriate costimulatory signal, the clonal expansion of T cells bearing a T cell receptor that specifically recognizes the peptide / MHC complex.

[0097] Preferably, the T cell epitope comprises an amino acid sequence which substantially corresponds to the amino acid sequence of a fragment of an antigen. Preferably, said fragment of an antigen is an MHC class I and / or class II presented peptide.

[0098] A T cell epitope according to the present invention preferably relates to an antigen or a part or fragment of an antigen capable of stimulating an immune response, preferably a cellular response, against a cell characterized by expression of the antigen, preferably by presentation of the antigen, such as a diseased cell, in particular a cancer cell. Preferably, the T cell epitope is capable of stimulating a cellular response against a cell characterized by presentation of an antigen with class I MHC, preferably capable of stimulating an antigen-responsive cytotoxic T lymphocyte (CTL).

[0099] In some embodiments, the antigen is a self-antigen, in particular a tumor antigen. Tumor antigens and their determination are known to those of skill in the art.

[0100] The term "immunogenicity" preferably relates to the relative effectiveness for inducing an immune response relevant to a therapeutic treatment, such as a treatment against cancer. As used herein, the term "immunogenic" relates to the property of having immunogenicity. For example, the term "immunogenic modification", when used in the context of a peptide, polypeptide or protein, relates to the effectiveness of said peptide, polypeptide or protein for inducing an immune response resulting from and / or directed against said modification. Preferably, the unmodified peptide, polypeptide or protein does not induce an immune response, induces a different immune response, or induces a different level, preferably a lower level, of an immune response.

[0101] According to the present invention, the term "immunogenicity" or "immunogenic" preferably relates to the relative effectiveness for inducing a biologically relevant immune response, in particular an immune response useful for vaccination. Thus, in a preferred embodiment, an amino acid modification or modified peptide is immunogenic if it induces an immune response against the target modification in a subject, which immune response can be beneficial for therapeutic or prophylactic purposes.

[0102] "Antigen processing" or "processing" refers to the degradation of a polypeptide or antigen into processing products of fragments of said polypeptide or antigen (e.g., degradation of a polypeptide into peptides), and the association (e.g., by binding) of one or more of these fragments with an MHC molecule for presentation to specific T cells by a cell, preferably an antigen-presenting cell.

[0103] An "antigen-presenting cell" (APC) is a cell that presents peptide fragments of protein antigens in association with MHC molecules on its cell surface. Some APCs can activate antigen-specific T cells.

[0104] Professional antigen-presenting cells are highly efficient at internalizing antigens, either by phagocytosis or receptor-mediated endocytosis, and then displaying fragments of the antigen bound to class II MHC molecules on their membrane. T cells recognize and interact with the antigen-class II MHC molecule complex on the membrane of antigen-presenting cells. Further costimulatory signals are then generated by the antigen-presenting cells, leading to T cell activation. The expression of costimulatory molecules is a defining feature of professional antigen-presenting cells.

[0105] The main types of professional antigen-presenting cells are dendritic cells, which have the broadest range of antigen presentation and are perhaps the most important antigen-presenting cells, macrophages, B-cells, and certain activated epithelial cells.

[0106] Dendritic cells (DCs) are a population of leukocytes that present antigens captured in peripheral tissues to T cells by both MHC class II and I antigen presentation pathways. It is well known that dendritic cells are potent inducers of immune responses and activation of these cells is a key step in the induction of antitumor immunity. Dendritic cells are conveniently classified into "immature" and "mature" cells, which can be used as a simple way to distinguish between two well-characterized phenotypes. However, this nomenclature should not be interpreted as excluding all possible intermediate stages of differentiation. Immature dendritic cells are characterized as antigen-presenting cells with a high capacity for antigen uptake and processing, which correlates with high expression of Fcγ receptors and mannose receptors. The mature phenotype is typically characterized by lower expression of these markers but high expression of cell surface molecules responsible for T cell activation, such as class I and class II MHC, adhesion molecules (e.g., CD54 and CD11), and costimulatory molecules (e.g., CD40, CD80, CD86, and 4-1BB).

[0107] Dendritic cell maturation refers to a state of dendritic cell activation in which such antigen-presenting dendritic cells result in T cell priming, while presentation by immature dendritic cells results in tolerance. Dendritic cell maturation is primarily triggered by biomolecules with microbial signatures (bacterial DNA, viral RNA, endotoxins, etc.) detected by innate receptors, proinflammatory cytokines (TNF, IL-1, IFN), ligation of CD40 on the dendritic cell surface by CD40L, and substances released from cells undergoing stress-induced cell death. Dendritic cells can be induced by culturing bone marrow cells in vitro with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor alpha.

[0108] Non-professional antigen-presenting cells do not constitutively express the MHC class II proteins required for interaction with naive T cells: these are expressed only upon stimulation of the non-professional antigen-presenting cells with specific cytokines such as IFNγ.

[0109] An "antigen-presenting cell" can be loaded with an MHC class I-presented peptide by transducing the cell with a nucleic acid, preferably RNA, encoding a peptide or polypeptide, including the peptide to be presented, e.g., a nucleic acid encoding an antigen.

[0110] In some embodiments, the pharmaceutical compositions or vaccines of the present invention comprising gene delivery vehicles targeted to dendritic or other antigen-presenting cells can be administered to patients, resulting in transfection occurring in vivo. For example, in vivo transfection of dendritic cells can be performed using any method known in the art, such as the gene gun approach generally described in WO 97 / 24447 or by Mahvi et al., Immunology and cell Biology 75:456-460, 1997.

[0111] The term "antigen-presenting cells" also includes target cells.

[0112] "Target cell" is intended to mean a cell that is the target of an immune response, such as a cellular immune response. Target cells include cells that present an antigen or an antigen epitope, i.e. a peptide fragment derived from an antigen, and include any undesirable cell, such as a cancer cell. In a preferred embodiment, a target cell is a cell that expresses an antigen as described herein, and preferably presents said antigen using class I MHC.

[0113] The term "portion" refers to a fraction. With respect to a particular structure, such as an amino acid sequence or a protein, the term "portion" may designate a continuous or discontinuous fraction of said structure. Preferably, a portion of an amino acid sequence comprises at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, preferably at least 40%, preferably at least 50%, more preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the amino acids of said amino acid sequence. Preferably, when the portion is a discontinuous fraction, said discontinuous fraction is composed of 2, 3, 4, 5, 6, 7, 8 or more portions of the structure, each portion being a continuous element of the structure. For example, a non-contiguous fraction of an amino acid sequence may consist of 2, 3, 4, 5, 6, 7, 8 or more, preferably 4 or less, portions of said amino acid sequence, each portion preferably comprising at least 5 consecutive amino acids, at least 10 consecutive amino acids, preferably at least 20 consecutive amino acids, preferably at least 30 consecutive amino acids of the amino acid sequence.

[0114] The terms "portion" and "fragment" are used interchangeably herein and refer to a continuous element. A portion of a structure, such as an amino acid sequence or a protein, refers to a continuous element of said structure. A portion, part or fragment of a structure preferably comprises one or more functional properties of said structure. For example, a portion, part or fragment of an epitope, peptide or protein is preferably immunologically equivalent to the epitope, peptide or protein from which it is derived. In the context of the present invention, a "portion" of a structure, such as an amino acid sequence, preferably comprises, preferably consists of, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98%, at least 99% of the entire structure or amino acid sequence.

[0115] The term "immunoreactive cells" in the context of the present invention relates to cells that exert effector functions during an immune response. "Immunoreactive cells" are preferably capable of binding to cells characterized by the presentation of antigens or antigenic peptides derived from antigens and mediating an immune response. For example, such cells secrete cytokines and / or chemokines, secrete antibodies, recognize cancer cells and optionally eliminate such cells. For example, immunoreactive cells include T cells (cytotoxic T cells, helper T cells, tumor infiltrating T cells), B cells, natural killer cells, neutrophils, macrophages and dendritic cells. Preferably, in the context of the present invention, "immunoreactive cells" are T cells, preferably CD4 + and / or CD8 + T cells.

[0116] Preferably, an "immunoreactive cell" recognises with some degree of specificity an antigen or an antigenic peptide derived from an antigen, especially when presented in the context of an MHC molecule, such as on the surface of an antigen presenting cell or a diseased cell, such as a cancer cell. Preferably, said recognition enables the cell recognising the antigen or an antigenic peptide derived from said antigen to become responsive or reactive. The cell may be a helper T cell (CD4 T cell) bearing a receptor that recognises the antigen or an antigenic peptide derived from the antigen in the context of an MHC class II molecule. + In the case of CD8 T cells, such responsiveness or reactivity may be determined by the release of cytokines and / or CD8 + The responsiveness may include activation of lymphocytes (CTL) and / or B cells. If the cell is a CTL, such responsiveness or reactivity may include elimination of cells presented in the context of MHC class I molecules, i.e., cells characterized by presentation of antigen with class I MHC, for example by apoptosis or perforin-mediated cytolysis. CTL responsiveness may include sustained calcium flux, cell division, production of cytokines such as IFN-γ and TNF-α, upregulation of activation markers such as CD44 and CD69, and specific cytolytic killing of antigen-expressing target cells. CTL responsiveness may also be determined using artificial reporters that pinpoint CTL responsiveness. Such CTLs that recognize and are responsive or reactive to an antigen or an antigenic peptide derived from an antigen are also referred to herein as "antigen-responsive CTLs". If the cell is a B cell, such responsiveness may include release of immunoglobulins.

[0117] The terms "T cells" and "T lymphocytes" are used interchangeably herein and include T helper cells (CD4+ T cells) and cytotoxic T cells (CTL, CD8+ T cells), including cytolytic T cells.

[0118] T cells belong to a group of white blood cells known as lymphocytes and play a central role in cell-mediated immunity. They can be distinguished from other lymphocyte types, such as B cells and natural killer cells, by the presence of a special receptor on their cell surface called the T cell receptor (TCR). The thymus is the main organ responsible for the maturation of T cells. Several different subsets of T cells have been discovered, each with distinct functions.

[0119] T helper cells assist other white blood cells in immune processes, including, among other functions, maturation of B cells into plasma cells and activation of cytotoxic T cells and macrophages. These cells express the CD4 protein on their surface and are therefore also known as CD4+ T cells. Helper T cells are activated upon presentation of peptide antigens by MHC class II molecules expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in active immune responses.

[0120] Cytotoxic T cells destroy virus-infected and tumor cells and are also associated with transplant rejection. These cells are also known as CD8+ T cells because they express the CD8 glycoprotein on their surface. These cells recognize their targets by binding to antigens associated with MHC class I, which is present on the surface of almost every cell in the body.

[0121] In the majority of T cells, the T cell receptor (TCR) exists as a complex of several proteins. The actual T cell receptor is composed of two separate peptide chains produced by independent T cell receptor alpha and beta (TCRα and TCRβ) genes, called α- and β-TCR chains. γδ T cells (gamma delta T cells) represent a small subset of T cells that carry distinct T cell receptors (TCRs) on their surface. However, in γδ T cells, the TCR consists of one γ-chain and one δ-chain. This group of T cells is much rarer than αβ T cells (2% of all T cells).

[0122] According to the present invention, the term "antigen receptor" includes naturally occurring receptors such as T cell receptors and engineered receptors that confer any specificity, such as the specificity of monoclonal antibodies, on immune effector cells such as T cells. In this way, large numbers of antigen-specific T cells can be generated for adoptive cell transfer. Thus, an antigen receptor according to the present invention can be present on a T cell, for example, instead of or in addition to the T cell's own T cell receptor. Such T cells do not necessarily require antigen processing and presentation for recognition of the target cell, but rather can recognize any antigen present on the target cell, preferably with specificity. Preferably, said antigen receptor is expressed on the surface of the cell. For the purposes of the present invention, T cells comprising an antigen receptor are encompassed by the term "T cell" as used herein. In particular, according to the present invention, the term "antigen receptor" includes an artificial receptor comprising a single molecule or a complex of molecules that can recognize, i.e. bind to, a target structure (e.g., an antigen) in a target cell, such as a cancer cell (e.g., by binding of an antigen binding site or antigen binding domain to an antigen expressed on the surface of the target cell) and confer specificity to an immune effector cell, such as a T cell, expressing said antigen receptor on its cell surface. Preferably, recognition of the target structure by the antigen receptor results in activation of an immune effector cell expressing said antigen receptor. An antigen receptor can comprise one or more protein units, said protein units comprising one or more domains as described herein. According to the present invention, an "antigen receptor" can be a "chimeric antigen receptor (CAR)", a "chimeric T cell receptor" or an "artificial T cell receptor".

[0123] An antigen can be recognized by an antigen receptor through any antigen recognition domain (also referred to herein simply as "domain") capable of forming an antigen binding site, such as through the antigen binding portion of an antibody and a T-cell receptor, which can reside on the same or different peptide chains. In one embodiment, the two domains forming the antigen binding site are derived from an immunoglobulin. In one embodiment, the two domains forming the antigen binding site are derived from a T-cell receptor. Antibody variable domains are particularly preferred, such as single chain variable fragments (scFv) derived from monoclonal antibodies and T-cell receptor variable domains, especially TCR alpha and beta single chains. Virtually anything that binds to a given target with high affinity can be used as an antigen recognition domain.

[0124] The first signal in T cell activation is provided by the binding of the T cell receptor to a short peptide presented by the major histocompatibility complex (MHC) on another cell. This ensures that only T cells with a TCR specific for that peptide are activated. The partner cell is usually a professional antigen presenting cell (APC), usually a dendritic cell in the case of a naive response, but B cells and macrophages can also be important APCs. Peptides presented to CD8+ T cells by MHC class I molecules are typically 8-10 amino acids long; peptides presented to CD4+ T cells by MHC class II molecules are typically longer, because the binding cleft of MHC class II molecules is open at the end.

[0125] According to the present invention, a molecule is capable of binding to a predetermined target if it has a significant affinity for the target in a standard assay and binds to said predetermined target. "Affinity" or "binding affinity" is often measured using the equilibrium dissociation constant (K D A molecule is (substantially) incapable of binding to a target if it has no significant affinity for the target in a standard assay and does not bind significantly to said target.

[0126] Cytotoxic T lymphocytes can be generated in vivo by incorporating antigens or antigenic peptides into antigen-presenting cells in vivo. The antigens or antigenic peptides can be presented as proteins, as DNA (e.g. in vectors), or as RNA. Antigens can be processed to produce peptide partners of MHC molecules, while fragments thereof can be presented without further processing, especially in the latter situation if they are able to bind to MHC molecules. In general, administration to patients by intradermal injection is possible. However, intranodal injection into lymph nodes can also be performed (Maloy et al., 2001, Proc Natl Acad Sci USA 98:3299-303). The resulting cells present the complex of interest and are recognized by autologous cytotoxic T lymphocytes, which then proliferate.

[0127] Specific activation of CD4+ or CD8+ T cells can be detected in various ways. Methods for detecting specific T cell activation include detecting T cell proliferation, cytokine (e.g., lymphokine) production, or the occurrence of cytolytic activity. For CD4+ T cells, the preferred method for detecting specific T cell activation is detecting T cell proliferation. For CD8+ T cells, the preferred method for detecting specific T cell activation is detecting the occurrence of cytolytic activity.

[0128] "Cells characterized by antigen presentation" or "cells presenting antigen" or similar expressions refer to cells, such as diseased cells, e.g. cancer cells, or antigen-presenting cells, that present the antigen they express or a fragment derived from said antigen, e.g. by processing the antigen, in the context of MHC molecules, particularly MHC class I molecules. Similarly, the term "diseases characterized by antigen presentation" refers to diseases involving cells that are characterized by antigen presentation, particularly using class I MHC. Presentation of antigen by cells can be achieved by transfecting the cells with a nucleic acid, such as an RNA, encoding the antigen.

[0129] By "fragment of a presented antigen" or similar expressions is meant a fragment that, for example when added directly to an antigen presenting cell, can be presented by MHC class I or class II, preferably MHC class I. In one embodiment, the fragment is a fragment that is naturally presented by a cell expressing the antigen.

[0130] The term "immunologically equivalent" means that immunologically equivalent molecules, such as immunologically equivalent amino acid sequences, exhibit the same or essentially the same immunological properties and / or exert the same or essentially the same immunological effect, e.g., in terms of the type of immunological effect, such as induction of a humoral and / or cellular immune response, the strength and / or duration of the induced immune response, or the specificity of the induced immune response. In the context of the present invention, the term "immunologically equivalent" is preferably used in reference to the immunological effect or properties of a peptide used for immunization. For example, an amino acid sequence is immunologically equivalent to a reference amino acid sequence if, when exposed to the immune system of a subject, said sequence induces an immune response with specificity reactive with the reference amino acid sequence.

[0131] The term "immune effector function" in the context of the present invention includes any function mediated by components of the immune system that results in, for example, the killing of tumor cells, or the inhibition of tumor growth and / or the inhibition of tumorigenesis, including the inhibition of tumor intracellular and metastatic spread. Preferably, immune effector functions in the context of the present invention are effector functions mediated by T cells. Such functions include those mediated by helper T cells (CD4 + In the case of T cells, recognition of an antigen or an antigenic peptide derived from an antigen by a T cell receptor in the context of an MHC class II molecule, release of cytokines and / or CD8 +This includes activation of lymphocytes (CTLs) and / or B cells, in the case of CTLs, recognition of the antigen or antigenic peptides derived from the antigen by the T cell receptor in the context of MHC class I molecules, elimination of cells presented in the context of MHC class I molecules, i.e. cells characterized by presentation of the antigen with class I MHC, e.g., by apoptosis or perforin-mediated cytolysis, production of cytokines such as IFN-γ and TNF-α, and specific cytolytic killing of antigen-expressing target cells.

[0132] The term "major histocompatibility complex" and the abbreviation "MHC" refer to a complex of genes that includes MHC class I and MHC class II molecules and occurs in all vertebrates. MHC proteins or molecules are important in signaling between lymphocytes and antigen-presenting or diseased cells in an immune response; MHC proteins or molecules bind peptides and present them for recognition by T cell receptors. Proteins encoded by MHC are expressed on the surface of cells and display both self antigens (peptide fragments derived from the cell itself) and non-self antigens (e.g., fragments of invading microorganisms) to T cells.

[0133] The MHC region is divided into three subgroups, class I, class II and class III. MHC class I proteins contain an alpha chain and beta2 microglobulin (not the part of the MHC encoded by chromosome 15), which present antigen fragments to cytotoxic T cells. In most immune system cells, particularly antigen presenting cells, MHC class II proteins contain an alpha and a beta chain, which present antigen fragments to T helper cells. The MHC class III region codes for other immune components such as complement components, some of which code for cytokines.

[0134] The MHC is both polygenic (there are several MHC class I and MHC class II genes) and polymorphic (there are multiple alleles of each gene).

[0135] As used herein, the term "haplotype" refers to the HLA alleles found on one chromosome and the proteins encoded thereby. Haplotype can also refer to the alleles present at any one locus in the MHC. Each class of MHC is represented by several loci: for example, class I is HLA-A (human leukocyte antigen-A), HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-P and HLA-V, and class II is HLA-DRA, HLA-DRB1-9, HLA-DQA1, HLA-DQB1, HLA-DPA1, HLA-DPB1, HLA-DMA, HLA-DMB, HLA-DOA and HLA-DOB. The terms "HLA allele" and "MHC allele" are used interchangeably herein.

[0136] The MHC exhibits extreme polymorphism: within the human population, at each locus, there exist numerous haplotypes containing distinct alleles. Different polymorphic MHC alleles, both class I and class II, have different peptide specificities, in that each allele encodes a protein that binds to peptides exhibiting a particular sequence pattern.

[0137] In the context of the present invention, the MHC molecule is preferably an HLA molecule.

[0138] In the context of the present invention, the term "MHC binding peptide" includes MHC class I and / or class II binding peptides, or peptides that can be processed to produce MHC class I and / or class II binding peptides. For class I MHC / peptide complexes, the binding peptides are typically 8-12, preferably 8-10 amino acids in length, although longer or shorter peptides may be effective. For class II MHC / peptide complexes, the binding peptides are typically 9-30, preferably 10-25, especially 13-18 amino acids in length, although longer and shorter peptides may be effective.

[0139] "Antigenic peptide" preferably relates to an antigen or a part or fragment of an antigen capable of stimulating an immune response, preferably a cellular response, against a diseased cell, in particular a cancer cell, characterized by expression of the antigen, preferably by presentation of the antigen. Preferably, the antigenic peptide is capable of stimulating a cellular response against a cell characterized by presentation of the antigen with class I MHC, preferably capable of stimulating antigen-responsive cytotoxic T lymphocytes (CTLs). Preferably, the antigenic peptide is an MHC class I and / or class II presented peptide or can be processed to produce an MHC class I and / or class II presented peptide. Preferably, the antigenic peptide comprises an amino acid sequence substantially corresponding to the amino acid sequence of a fragment of the antigen. Preferably, said fragment of the antigen is an MHC class I and / or class II presented peptide. Preferably, the antigenic peptide comprises an amino acid sequence substantially corresponding to the amino acid sequence of such a fragment and is processed to produce such a fragment, i.e. an MHC class I and / or class II presented peptide derived from the antigen.

[0140] The peptides, where they need to be presented directly, i.e. without processing, in particular without cleavage, have a length suitable for binding to MHC molecules, in particular class I MHC molecules, and are preferably 7 to 20 amino acids in length, more preferably 7 to 12 amino acids in length, more preferably 8 to 11 amino acids in length, in particular 9 or 10 amino acids in length.

[0141] If the peptide is part of a larger entity comprising additional sequences, e.g. vaccine sequences or polypeptides, and needs to be presented after processing, in particular after cleavage, the peptide produced by processing has a length suitable for binding to MHC molecules, in particular class I MHC molecules, preferably 7-20 amino acids long, more preferably 7-12 amino acids long, more preferably 8-11 amino acids long, in particular 9 or 10 amino acids long. Preferably, the sequence of the peptide that needs to be presented after processing is derived from the amino acid sequence of the antigen, i.e. the sequence corresponds substantially to, preferably completely identical to, a fragment of the antigen. Thus, the MHC-binding peptide comprises a sequence that corresponds substantially to, preferably completely identical to, a fragment of the antigen.

[0142] Peptides with amino acid sequences that substantially correspond to the sequence of a peptide presented by class I MHC may differ in one or more residues that are not essential for TCR recognition of the peptide presented by class I MHC or for binding of the peptide to MHC. Such substantially corresponding peptides can also stimulate antigen-responsive CTLs and can be considered immunologically equivalent. Peptides with amino acid sequences that differ from the presented peptide in residues that do not affect TCR recognition but improve the stability of binding to MHC can improve the immunogenicity of the antigenic peptide and can be referred to herein as "optimized peptides". Using existing knowledge of which of these residues may be more likely to affect binding to either MHC or TCR, a rational approach can be used for the design of substantially corresponding peptides. The resulting peptides that are functional are considered antigenic peptides.

[0143] The antigenic peptide, when presented by MHC, should be recognizable by a T cell receptor. Preferably, the antigenic peptide, when recognized by the T cell receptor, is capable of inducing, in the presence of an appropriate co-stimulatory signal, clonal expansion of T cells bearing a T cell receptor that specifically recognizes the antigenic peptide. Preferably, the antigenic peptide, especially when presented in the context of an MHC molecule, is capable of stimulating an immune response, preferably a cellular response, against the antigen from which it originates, or against a cell characterized by the expression of the antigen, preferably characterized by the presentation of the antigen. Preferably, the antigenic peptide is capable of stimulating a cellular response against a cell characterized by the presentation of the antigen with class I MHC, preferably stimulating an antigen-responsive CTL. Such a cell is preferably a target cell.

[0144] The term "genome" relates to the total amount of genetic information in the chromosomes of an organism or cell.

[0145] The term "exome" refers to the portion of an organism's genome formed by exons, the coding portions of expressed genes. The exome provides the genetic blueprint used in the synthesis of proteins and other functional gene products. It is the most functionally relevant part of the genome and therefore most likely to contribute to the organism's phenotype. It has been estimated that the exome of the human genome constitutes 1.5% of the entire genome (Ng et al., 2008, PLoS Gen., 4(8):1-15).

[0146] The term "transcriptome" refers to the set of all RNA molecules, including mRNA, rRNA, tRNA and other non-coding RNA, produced in a cell or a population of cells. In the context of the present invention, transcriptome or RNA sequence refers to the set of all RNA molecules produced in a cell, a population of cells, preferably a population of cancer cells, or in every cell of a given individual at a given time.

[0147] "Nucleic acid" is preferably deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), more preferably RNA, most preferably in vitro transcribed RNA (IVT RNA) or synthetic RNA. Nucleic acid includes genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules. Nucleic acids may exist as single-stranded or double-stranded linear or covalently closed circular molecules. Nucleic acids can be isolated. The term "isolated nucleic acid" means that the nucleic acid is (i) amplified in vitro, e.g., by polymerase chain reaction (PCR), (ii) recombinantly produced by cloning, (iii) purified, e.g., by cleavage and separation by gel electrophoresis, or (iv) synthesized, e.g., by chemical synthesis. Nucleic acids can be used for introduction into cells, i.e., transfection, in particular in the form of RNA, which can be prepared by in vitro transcription from a DNA template. RNA can be further modified by stabilizing sequences, capping, and polyadenylation before application.

[0148] The term "genetic material" refers to isolated nucleic acids, either DNA or RNA, a section of a double helix, a section of a chromosome, or the entire genome of an organism or cell, particularly its exome or transcriptome.

[0149] The term "mutation" refers to a change or difference (nucleotide substitution, addition or deletion) in a nucleic acid sequence in an affected genome compared to a reference, preferably matched normal genome. "Somatic mutations" may occur in any of the cells of the body other than germ cells (sperm and eggs) and therefore are not passed on to offspring. These changes may (but do not necessarily) cause cancer or other diseases. Preferably, the mutation is a nonsynonymous mutation. The term "nonsynonymous mutation" refers to a mutation, preferably a nucleotide substitution, that results in an amino acid change, such as an amino acid substitution, in the translation product, preferably resulting in the formation of a neo-epitope.

[0150] The term "single nucleotide variant / variation (SNV)" refers to a difference in a nucleic acid sequence at a specific site (allele) when comparing a genome from a diseased cell, such as a tumor cell, and preferably a matched (corresponding) genome of a normal, non-diseased cell or reference genome. As used herein, the term mutation preferably encompasses SNVs.

[0151] A copy number variation (CNV) event in an affected (tumor) genome is a somatic copy number variation event occurring only in affected cells and is defined as an alteration in the number of copies of the maternal and / or paternal alleles of a region of the affected (tumor) genome relative to a matched normal genome, preferably affecting a region of the genome spanning approximately 1 kb or more.

[0152] The term "mutation" includes point mutations, indels, fusions, chromosomal cleavage and RNA editing.

[0153] The term "indel" describes a special class of mutations, defined as mutations that result in coexisting insertions and deletions and net gains or losses of nucleotides. In the coding regions of the genome, indels will result in frameshift mutations unless their length is a multiple of three. Indels can be contrasted with point mutations. Where indels insert and delete nucleotides from a sequence, point mutations are a form of substitution that replaces one of the nucleotides.

[0154] Fusions can result in hybrid genes formed from two previously separate genes. This can occur as a result of translocations, interstitial deletions, or chromosomal inversions. In many cases, the fusion gene is an oncogene. Oncogenic fusion genes can result in new or different functional gene products from the two fusion partners. Alternatively, the proto-oncogene is fused to a strong promoter, and thus the oncogenic function begins to function by upregulation caused by the strong promoter of the upstream fusion partner. Oncogenic fusion transcripts can also be caused by trans-splicing or read-through events.

[0155] The term "chromosipsis" refers to a genetic phenomenon in which a specific region of the genome is shattered and then sutured back together by a single disruption event.

[0156] The term "RNA editing" or "editing RNA" refers to a molecular process in which the information content in an RNA molecule is altered by chemical changes in the base makeup. RNA editing includes nucleoside modifications such as cytidine (C) to uridine (U) and adenosine (A) to inosine (I), deamination, and non-templated nucleotide additions and insertions. RNA editing of mRNA effectively changes the amino acid sequence of the encoded protein to differ from that predicted by the genomic DNA sequence.

[0157] The term "cancer mutational signature" refers to a set of mutations that are present in cancer cells when compared to non-cancerous reference cells.

[0158] "Reference" in the context of the present invention can be used to correlate and compare the results obtained from tumor samples.Typically, "reference" can be obtained based on one or more normal samples, particularly samples not affected by cancer disease, obtained either from the patient or from one or more different individuals, preferably from healthy individuals, particularly from individuals of the same species."Reference" can be empirically determined by testing a sufficiently large number of normal samples.

[0159] The term "reference genome" refers to a genome that provides a coordinate system for normal and affected genomes. The reference genome is used to map read data and provide a coordinate system for normal and tumor genomes, which allows for providing chromosome number, nucleotide position in chromosome, and directionality of read data. The reference genome can be based on the genome of one or more members from the same species as the subject providing the affected sample, or can be based on the normal genome (matched genome) of the subject.

[0160] Any suitable sequencing method can be used in the context of the present invention to identify disease-specific mutations, with next-generation sequencing (NGS) technology being preferred, optionally in combination with SNP arrays to obtain absolute copy number information. To speed up the sequencing step of the method, third-generation sequencing methods may replace NGS technology in the future. For the purpose of clarity, the term "next-generation sequencing" or "NGS" in the context of the present invention refers to all novel high-throughput sequencing technologies, in contrast to the "conventional" sequencing method known as Sanger chemistry, which randomly reads a nucleic acid template in parallel along the entire genome by cutting the genome into small pieces. Such NGS technologies (also known as massively parallel sequencing technologies) can deliver nucleic acid sequence information of the whole genome, exome, transcriptome (all transcribed sequences of the genome) or methylome (all methylated sequences of the genome) in a very short time, e.g., within 1-2 weeks, preferably within 1-7 days, or most preferably within less than 24 hours, in principle enabling single-cell sequencing approaches. Several NGS platforms, commercially available or as mentioned in the literature, for example those detailed in Zhang et al., 2011, The impact of next-generation sequencing on genomics. J. Genet Genomics 38(3): 95-109 or Voelkerding et al., 2009, Next generation sequencing: From basic research to diagnostics. Clinical chemistry 55: 641-658, can be used in the context of the present invention. Non-limiting examples of such NGS technologies / platforms are as follows: 1) Sequencing by synthesis technique known as pyrosequencing, implemented for example in the GS-FLX 454 Genome Sequencer™ from Roche affiliate 454 Life Sciences, Inc. (Branford, CT), first described in Ronaghi et al., 1998, A sequencing method based on real-time pyrophosphate, Science 281: 363-365. This technique uses emulsion PCR, in which single-stranded DNA-binding beads are encapsulated by vigorous vortexing in aqueous micelles containing PCR reactants surrounded by oil for emulsion PCR amplification. During the pyrosequencing process, light emitted from phosphate molecules during incorporation of nucleotides as polymerase synthesizes DNA strands is recorded. 2) Sequencing by synthesis, developed by Solexa (now part of Illumina Inc., San Diego, CA), which is based on reversible dye-terminators and implemented, for example, in the Illumina / Solexa Genome Analyzer™ and Illumina HiSeq 2000 Genome Analyzer™. In this technology, all four nucleotides are added simultaneously to oligo-primed cluster fragments in a flow cell channel along with DNA polymerase. Bridge amplification extends the cluster strands with all four fluorescently labeled nucleotides for sequencing. 3) Sequencing by ligation, for example as implemented in the SOLid™ platform from Applied Biosystems (now Life Technologies Corporation, Carlsbad, CA). In this technique, a pool of all possible oligonucleotides of fixed length is labeled according to the position to be sequenced. The oligonucleotides are annealed and ligated, and preferential ligation of matching sequences by DNA ligase results in an informative signal of the nucleotide at that position. Prior to sequencing, DNA is amplified by emulsion PCR. The resulting beads, each containing only copies of the same DNA molecule, are placed on a glass slide. As a second example, the Polonator™ G.007 platform from Dover Systems (Salem, NH) also uses sequencing by ligation by using emulsion PCR based on randomly arrayed beads to amplify DNA fragments for parallel sequencing. 4) Single molecule sequencing technology, for example implemented in the PacBio RS system from Pacific Biosciences (Menlo Park, CA) or the HeliScope™ platform from Helicos Biosciences (Cambridge, MA). The defining feature of this technology is its ability to sequence single DNA or RNA molecules without amplification, defined as single molecule real-time (SMRT) DNA sequencing. For example, HeliScope uses a highly sensitive fluorescence detection system to directly detect each nucleotide as it is synthesized. A similar approach based on fluorescence resonance energy transfer (FRET) has been developed by Visigen Biotechnology (Houston, TX). Other fluorescence-based single molecule techniques are from USGenomics (GeneEngine™) and Genovoxx (AnyGene™). 5) Nanotechnology for single molecule sequencing, using various nanostructures arranged on a chip to monitor the movement of polymerase molecules on a single strand, for example during replication. Non-limiting examples of nanotechnology-based approaches are the GridON™ platform from Oxford Nanopore Technologies (Oxford, UK), the Hybridization-Assisted Nanopore Sequencing (HANS™) platform developed by Nabsys (Providence, RI), and a proprietary ligase-based DNA sequencing platform using DNA nanoball (DNB) technology called combinatorial probe anchor ligation (cPAL™). 6) Electron microscopy-based techniques for single molecule sequencing, such as those developed by LightSpeed ​​Genomics (Sunnyvale, Calif.) and Halcyon Molecular (Redwood City, Calif.). 7) Ion semiconductor sequencing, based on the detection of hydrogen ions released during DNA polymerization. For example, Ion Torrent Systems (San Francisco, CA) uses a high-density array of micro-measurement wells to perform this biochemical process in a massively parallel fashion. Each well contains a different DNA template. Beneath the well is an ion-sensitive layer, and beneath that is a proprietary ion sensor.

[0161] In one embodiment, as disclosed in the International PCT patent application entitled "Highly Accurate Mutation Detection, In Particular for Personalized Therapeutics" filed on the same date hereof, the entire disclosure of which is incorporated herein by reference, whether a disease-specific mutation has occurred can be determined by a method involving determining that a site in the normal genome matches a homozygous genotype reflected by a normal allele and three noise alleles and an ideal noise distribution, a mutation is declared if the corresponding site in the tumor genome does not match the homozygous genotype and ideal noise distribution, and the read data matches the ideal noise distribution if the read data maps to each of the noise alleles with a probability of one-third of the error rate per base.

[0162] Preferably, DNA and RNA preparations serve as starting materials for NGS. Such nucleic acids can be easily obtained from samples such as biological material, for example, from fresh, flash-frozen or formalin-fixed paraffin-embedded tumor tissue (FFPE) or from freshly isolated cells or from CTCs present in the peripheral blood of patients. Normal, non-mutated genomic DNA or RNA can be extracted from normal somatic tissue, but germline cells are preferred in the context of the present invention. Germline DNA or RNA is extracted from peripheral blood mononuclear cells (PBMCs) in patients suffering from non-hematological malignancies. Nucleic acids extracted from FFPE tissue or freshly isolated single cells are highly fragmented, but are suitable for NGS applications.

[0163] Several targeted NGS methods for exome sequencing have been described in the literature (for review, see, e.g., Teer and Mullikin, 2010, Human Mol Genet 19(2): R145-51), all of which can be used in conjunction with the present invention. Many of these methods (e.g., described as genome capture, genome partitioning, genome enrichment, etc.) use hybridization techniques and include array-based (e.g., Hodges et al., 2007, Nat. Genet. 39: 1522-1527) and liquid-based (e.g., Choi et al., 2009, Proc. Natl. Acad. Sci USA 106: 19096-19101) hybridization approaches. Commercially available kits are also available for DNA sample preparation and subsequent exome capture; for example, Illumina Inc. (San Diego, Calif.) offers the TruSeq™ DNA Sample Preparation Kit and the TruSeq™ Exome Enrichment Kit.

[0164] To reduce the number of false positive findings in the detection of cancer-specific somatic mutations or sequence differences when comparing, for example, the sequence of a tumor sample with the sequence of a reference sample, such as the sequence of a germline sample, it is preferred to determine the sequence in duplicates of one or both of these sample types. Therefore, it is preferred to determine the sequence of a reference sample, such as the sequence of a germline sample, two, three or more times. Alternatively or additionally, the sequence of a tumor sample is determined two, three or more times. It may also be possible to determine the sequence of a reference sample, such as the sequence of a germline sample, and / or the sequence of a tumor sample multiple times, by determining the sequence at least once in genomic DNA and determining the sequence at least once in RNA of said reference sample and / or said tumor sample. For example, by determining the mutations between duplicates of a reference sample, such as a germline sample, the expected false positive rate (FDR) of somatic mutations can be estimated as a statistical quantity. Technical replicates of one sample should produce identical results, and all mutations detected during this "pairwise comparison" are false positives. In particular, to determine the false discovery rate of somatic mutation detection in tumor samples relative to reference samples, the technical repeats of the reference samples can be used as a reference to estimate the number of false positives.Furthermore, various quality-related metrics (e.g., coverage or SNP quality) can be combined into a single quality score using machine learning techniques.Optionally, for a given somatic mutation, all other mutations with a higher quality score can be counted, which allows ranking of all mutations in the dataset.

[0165] In the context of the present invention, the term "RNA" refers to a molecule that comprises at least one ribonucleotide residue, and preferably is composed entirely or substantially of ribonucleotide residues. "Ribonucleotide" refers to a nucleotide that has a hydroxyl group at the 2' position of a β-D-ribofuranosyl group. The term "RNA" includes isolated RNA, such as double-stranded RNA, single-stranded RNA, partially or completely purified RNA, essentially pure RNA, synthetic RNA, and recombinantly produced RNA, such as modified RNA that differs from naturally occurring RNA by the addition, deletion, substitution and / or modification of one or more nucleotides. Such modifications can include, for example, the addition of non-nucleotide material to the end of the RNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in an RNA molecule can also include non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These modified RNAs can be referred to as analogs or analogs of naturally occurring RNA.

[0166] The term "RNA" includes and preferably relates to "mRNA". The term "mRNA" means "messenger RNA" and relates to a "transcript" that is generated by using a DNA template and encodes a peptide or polypeptide. Typically, an mRNA comprises a 5'-UTR, a protein coding region, and a 3'-UTR. An mRNA has a limited half-life in a cell and in vitro. In the context of the present invention, an mRNA may be generated by in vitro transcription from a DNA template. In vitro transcription methods are known to those skilled in the art. For example, various in vitro transcription kits are commercially available.

[0167] The stability and translation efficiency of RNA can be modified as necessary. For example, RNA can be stabilized and its translation increased by one or more modifications that have a stabilizing effect on RNA and / or increase translation efficiency. Such modifications are described, for example, in PCT / EP2006 / 009448, which is incorporated herein by reference. In order to increase the expression of the RNA used in the embodiments of the present invention, modifications can be made in the coding region, i.e., the sequence that codes for the peptide or protein to be expressed, preferably without changing the sequence of the peptide or protein to be expressed, to increase the GC content and increase the stability of mRNA, and to perform codon optimization, thus enhancing translation in cells.

[0168] As used herein, the term "modification" in the context of RNA includes any modification of RNA that does not naturally occur in said RNA.

[0169] In one embodiment of the invention, the RNA used according to the invention is free of uncapped 5'-triphosphates. Removal of such uncapped 5'-triphosphates can be achieved by treating the RNA with a phosphatase.

[0170] The RNA according to the present invention may have modified ribonucleotides to increase its stability and / or reduce its cytotoxicity.For example, in one embodiment, cytidine is partially or completely, preferably completely, replaced by 5-methylcytidine in the RNA used according to the present invention.Alternatively or additionally, in one embodiment, uridine is partially or completely, preferably completely, replaced by pseudouridine in the RNA used according to the present invention.

[0171] In one embodiment, the term "modification" relates to providing an RNA with a 5'-cap or a 5'-cap analog. The term "5'-cap" refers to the cap structure found on the 5' end of an mRNA molecule, which generally consists of a guanosine nucleotide linked to the mRNA via an unusual 5' to 5' triphosphate bond. In one embodiment, this guanosine is methylated at position 7. The term "conventional 5'-cap" refers to a naturally occurring RNA 5'-cap, preferably a 7-methylguanosine cap (m 7 In the context of the present invention, the term "5'-cap" includes 5'-cap analogs that resemble the RNA cap structure and are preferably modified to have the ability to stabilize RNA and / or enhance translation of RNA when attached thereto in vivo and / or within a cell.

[0172] Providing an RNA with a 5'-cap or 5'-cap analog may be achieved by in vitro transcription of a DNA template in the presence of the 5'-cap or 5'cap analog, where the 5'-cap is co-transcriptionally incorporated into the generated RNA strand, or the RNA may be generated, for example, by in vitro transcription, and the 5'-cap may be attached to the RNA post-transcriptionally using a capping enzyme, for example vaccinia virus capping enzyme.

[0173] The RNA may comprise further modifications. For example, further modifications of the RNA used in the present invention may be the extension or truncation of the naturally occurring poly(A) tail, or the introduction of a UTR not associated with the coding region of said RNA, for example the alteration of the 5'- or 3'-untranslated region (UTR), such as the replacement of an existing 3'-UTR with or the insertion of one or more, preferably two copies of a 3'-UTR from a globin gene, such as alpha2-globin, alpha1-globin, beta-globin, preferably beta-globin, more preferably human beta-globin.

[0174] RNA with an unmasked poly-A sequence is translated more efficiently than RNA with a masked poly-A sequence. The term "poly(A) tail" or "poly-A sequence" refers to a sequence of adenyl (A) residues typically located on the 3' end of an RNA molecule, and "unmasked poly-A sequence" means that the poly-A sequence at the 3' end of an RNA molecule ends with an A of the poly-A sequence and is not followed by any nucleotides other than A located at the 3' end, i.e. downstream, of the poly-A sequence. Furthermore, a long poly-A sequence of about 120 base pairs provides optimal transcriptional stability and translational efficiency of the RNA.

[0175] Therefore, in order to increase the stability and / or expression of the RNA used according to the invention, it may be modified so that it is present together with a poly-A sequence having a length of preferably 10 to 500, more preferably 30 to 300, even more preferably 65 to 200, in particular 100 to 150 adenosine residues. In a particularly preferred embodiment, the poly-A sequence has a length of about 120 adenosine residues. In order to further increase the stability and / or expression of the RNA used according to the invention, the poly-A sequence may be unmasked.

[0176] Furthermore, the incorporation of a 3'-untranslated region (UTR) into the 3'-untranslated region of an RNA molecule can result in increased translation efficiency. By incorporating two or more such 3'-untranslated regions, a synergistic effect can be achieved. The 3'-untranslated regions can be autologous or heterologous to the RNA into which they are introduced. In one particular embodiment, the 3'-untranslated region is derived from the human β-globin gene.

[0177] The combination of the above mentioned modifications, ie incorporation of a poly-A sequence, unmasking of a poly-A sequence and incorporation of one or more 3'-untranslated regions, has a synergistic effect on increasing RNA stability and translation efficiency.

[0178] The term "stability" of an RNA relates to the "half-life" of the RNA. "Half-life" relates to the period required to eliminate half of the activity, amount, or number of a molecule. In the context of the present invention, the half-life of an RNA is a measure of the stability of said RNA. The half-life of an RNA may affect the "duration of expression" of the RNA. An RNA with a long half-life can be expected to be expressed for a long period of time.

[0179] Of course, if it is desired to decrease the stability and / or translation efficiency of the RNA, it is possible to modify the RNA to interfere with the function of the above-mentioned elements that increase the stability and / or translation efficiency of the RNA.

[0180] The term "expression" is used in its most general sense and includes the production of RNA and / or peptides or polypeptides, for example by transcription and / or translation. With respect to RNA, the terms "expression" or "translation" particularly relate to the production of peptides or polypeptides. It also includes partial expression of a nucleic acid. Furthermore, expression can be transient or stable.

[0181] The term expression also includes "abnormal expression" or "abnormal expression". "Aberrant expression" or "abnormal expression" means that expression is altered, preferably increased, compared to a reference, e.g., the abnormal expression of a particular protein, e.g., a tumor antigen, or the state of a subject not suffering from a disease associated with the abnormal expression. Increased expression refers to an increase of at least 10%, in particular at least 20%, at least 50% or at least 100%, or more. In one embodiment, expression is found only in diseased tissues and expression in healthy tissues is suppressed.

[0182] The term "specifically expressed" means that a protein is expressed essentially only in a specific tissue or organ. For example, a tumor antigen specifically expressed in the gastric mucosa means that the protein is mainly expressed in the gastric mucosa and not in other tissues or not expressed to a significant extent in other tissues or organ types. Thus, a protein that is exclusively expressed in cells of the gastric mucosa and is expressed to a significantly lesser extent in any other tissue, such as the testis, is specifically expressed in cells of the gastric mucosa. In some embodiments, a tumor antigen may also be specifically expressed in multiple tissue types or organs, for example two or three tissue types or organs, but preferably not more than three different tissues or organ types, under normal conditions. In this case, the tumor antigen is specifically expressed in these organs. For example, if a tumor antigen is preferably expressed to about the same extent in the lung and stomach under normal conditions, the tumor antigen is specifically expressed in the lung and stomach.

[0183] In the context of the present invention, the term "transcription" refers to the process by which the genetic code of a DNA sequence is transcribed into RNA. The RNA can then be translated into a protein. According to the present invention, the term "transcription" includes "in vitro transcription", which refers to the process by which RNA, in particular mRNA, is synthesized in vitro in a cell-free system, preferably using a suitable cell extract. Preferably, a cloning vector is applied to generate the transcript. These cloning vectors are generally named transcription vectors and are encompassed by the term "vector". The RNA used in the present invention is preferably in vitro transcribed RNA (IVT-RNA) and can be obtained by in vitro transcription of a suitable DNA template. The promoter for controlling the transcription can be any promoter of any RNA polymerase. Particular examples of RNA polymerases are T7, T3 and SP6 RNA polymerases. Preferably, the in vitro transcription is controlled by the T7 or SP6 promoter. The DNA template for in vitro transcription can be obtained by cloning a nucleic acid, in particular a cDNA, and introducing it into a suitable vector for in vitro transcription. cDNA can be obtained by reverse transcription of RNA.

[0184] The term "translation" refers to the process in a cell's ribosomes in which a chain of messenger RNA directs the assembly of a sequence of amino acids to make a peptide or polypeptide.

[0185] In the context of the present invention, expression control sequences or regulatory sequences that can be operably linked to a nucleic acid can be homologous or heterologous with respect to the nucleic acid. A coding sequence and a regulatory sequence are "operably" linked together when they are covalently linked together such that the transcription or translation of the coding sequence is under the control or influence of the regulatory sequence. When the functional linkage between a regulatory sequence and a coding sequence is used to translate the coding sequence into a functional protein, the induction of the regulatory sequence results in the transcription of the coding sequence without causing a shift in the reading frame of the coding sequence or the coding sequence not being translated into the desired protein or peptide.

[0186] In the context of the present invention, the term "expression control sequence" or "regulatory sequence" includes promoters, ribosome binding sequences and other control elements that control the transcription of a nucleic acid or the translation of an induced RNA. In certain embodiments, the regulatory sequence can be controlled. The exact structure of the regulatory sequence may vary depending on the species or cell type, but generally includes 5'-non-transcribed and 5'- and 3'-non-translated sequences involved in the initiation of transcription or translation, such as TATA boxes, capping sequences, CAAT sequences, etc. In particular, 5'-non-transcribed regulatory sequences include promoter regions that include promoter sequences for transcriptional control of operably linked genes. Regulatory sequences can also include enhancer sequences or upstream activating sequences.

[0187] Preferably, the RNA to be expressed in the cell is introduced into said cell. In one embodiment of the method according to the invention, the RNA to be introduced into the cell is obtained by in vitro transcription of a suitable DNA template.

[0188] Terms such as "expressible RNA" and "encoding RNA" are used interchangeably herein and mean, in relation to a particular peptide or polypeptide, that the RNA, when present in the appropriate environment, preferably within a cell, is capable of being expressed to produce said peptide or polypeptide. Preferably, the RNA is capable of interacting with the cell's translation machinery to provide the peptide or polypeptide it is capable of expressing.

[0189] Terms such as "transfer", "introduce" or "transfect" are used interchangeably herein and relate to the introduction of a nucleic acid, particularly an exogenous or heterologous nucleic acid, particularly RNA, into a cell. According to the present invention, the cell may form part of an organ, tissue and / or organism. According to the present invention, administration of the nucleic acid is accomplished either as naked nucleic acid or in combination with an administration reagent. Preferably, administration of the nucleic acid is in the form of naked nucleic acid. Preferably, the RNA is administered in combination with a stabilizing agent such as an RNase inhibitor. The present invention also contemplates repeated introduction of the nucleic acid into the cell to allow long-term sustained expression.

[0190] Cells can be transfected with any carrier that can associate with RNA, for example by forming a complex with RNA or forming a vesicle that encloses or encapsulates RNA, and can provide increased stability of RNA compared to naked RNA.Useful carriers include, for example, cationic lipids, lipid-containing carriers such as liposomes, particularly cationic liposomes, and micelles, and nanoparticles.Cationic lipids can form complexes with negatively charged nucleic acids.Any cationic lipid can be used.

[0191] Preferably, introduction of RNA encoding a peptide or polypeptide into a cell, particularly a cell present in vivo, results in expression of said peptide or polypeptide in the cell. In certain embodiments, it is preferred to target the nucleic acid to a specific cell. In such embodiments, the carrier (e.g., retrovirus or liposome) applied to administer the nucleic acid to the cell exhibits a targeting molecule. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand of a receptor on the target cell may be incorporated into or bound to the nucleic acid carrier. When the nucleic acid is administered by liposome, a protein that binds to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation to enable targeting and / or uptake. Such proteins include capsid proteins or fragments thereof specific for a particular cell type, antibodies against proteins to be internalized, proteins that target intracellular locations, etc.

[0192] The term "cell" or "host cell" is preferably an intact cell, i.e. a cell with an intact membrane that has not released its normal intracellular components such as enzymes, organelles, or genetic material. An intact cell is preferably a living cell, i.e. a living cell capable of performing any normal metabolic function. Preferably, the term relates to any cell that can be transformed or transfected with an exogenous nucleic acid. The term "cell" includes prokaryotic cells (e.g. E. coli) or eukaryotic cells (e.g. dendritic cells, B cells, CHO cells, COS cells, K562 cells, HEK293 cells, HELA cells, yeast cells, and insect cells). Exogenous nucleic acids can be found in the cell (i) freely distributed by itself, (ii) incorporated in a recombinant vector, or (iii) integrated in the host cell genome or mitochondrial DNA. Mammalian cells, such as cells from humans, mice, hamsters, pigs, goats, and primates, are particularly preferred. The cells may be derived from a number of tissue types, including primary cells and cell lines. Specific examples include keratinocytes, peripheral blood leukocytes, bone marrow stem cells, and embryonic stem cells. In further embodiments, the cells are antigen-presenting cells, in particular dendritic cells, monocytes, or macrophages.

[0193] Cells containing the nucleic acid molecule preferably express the peptide or polypeptide encoded by the nucleic acid.

[0194] The term "clonal expansion" refers to the process of multiplication of a specific entity. In the context of the present invention, the term is preferably used in the context of an immunological response in which lymphocytes are stimulated by an antigen, proliferate, and specific lymphocytes that recognize said antigen are amplified. Preferably, clonal expansion leads to differentiation of lymphocytes.

[0195] Terms such as "reduce" or "inhibit" refer to the ability to cause a decrease in overall levels, preferably by 5% or more, 10% or more, 20% or more, more preferably by 50% or more, and most preferably by 75% or more. The term "inhibit" or similar phrases includes complete or essentially complete inhibition, i.e., a reduction to zero or essentially zero.

[0196] Terms such as "increase", "enhance", "promote" or "prolong" preferably relate to an increase, enhancement, promotion or prolongation of at least about 10%, preferably at least 20%, preferably at least 30%, preferably at least 40%, preferably at least 50%, preferably at least 80%, preferably at least 100%, preferably at least 200%, in particular at least 300%. These terms may also relate to an increase, enhancement, promotion or prolongation from zero or an unmeasurable or undetectable level to a level higher than zero or a measurable or detectable level.

[0197] According to the present invention, the term "peptide" refers to a substance comprising 2 or more, preferably 3 or more, preferably 4 or more, preferably 6 or more, preferably 8 or more, preferably 10 or more, preferably 13 or more, preferably 16 or more, preferably 21 or more, and preferably up to 8, 10, 20, 30, 40 or 50, in particular 100, amino acids covalently linked by peptide bonds. The term "polypeptide" or "protein" refers to a large peptide, preferably a peptide having more than 100 amino acid residues, but in general the terms "peptide", "polypeptide" and "protein" are synonymous and are used interchangeably herein. According to the present invention, the term "modification" or "sequence change" in relation to a peptide, polypeptide or protein relates to a sequence change in the peptide, polypeptide or protein compared to a parent sequence, such as the sequence of a wild type peptide, polypeptide or protein. This term includes amino acid insertion mutants, amino acid addition mutants, amino acid deletion mutants and amino acid substitution mutants, preferably amino acid substitution mutants. All these sequence changes according to the present invention can potentially generate new epitopes.

[0198] Amino acid insertion variants involve the insertion of one or two or more amino acids into a particular amino acid sequence.

[0199] Amino acid addition variants include amino- and / or carboxy-terminal fusions of one or more amino acids, such as 1, 2, 3, 4 or 5 or more amino acids.

[0200] Amino acid deletion variants are characterized by the removal of one or more amino acids from the sequence, for example the removal of 1, 2, 3, 4 or 5 or more amino acids.

[0201] Amino acid substitution variants are characterized by at least one residue in the sequence being removed and a different residue being inserted in its place.

[0202] According to the invention, the modification or modified peptide used for testing in the method of the invention can be derived from a protein that contains the modification.

[0203] According to the present invention, the term "derived from" means that a particular entity, in particular a particular peptide sequence, is present in the object from which it originates. In the case of amino acid sequences, in particular particular sequence regions, "derived from" means in particular that the relevant amino acid sequence is derived from the amino acid sequence in which it is present.

[0204] The agents, compositions and methods described herein can be used to treat subjects with diseases, such as diseases characterized by the presence of diseased cells that express antigens and present antigenic peptides. Particularly preferred diseases are cancer diseases. The agents, compositions and methods described herein can also be used for immunization or vaccination to prevent diseases described herein.

[0205] One such agent is a vaccine, such as a cancer vaccine designed based on suitable neoepitopes that resist immune evasion identified by the methods of the present invention.

[0206] According to the present invention, the term "vaccine" relates to a pharmaceutical preparation (pharmaceutical composition) or product which, upon administration, induces an immune response, in particular a cellular immune response, that recognizes and attacks pathogens or diseased cells, such as cancer cells. Vaccines can be used for the prevention or treatment of diseases. The term "personalized cancer vaccine" or "individualized cancer vaccine" refers to a specific cancer patient, meaning that the cancer vaccine is adapted to the needs or special circumstances of the individual cancer patient.

[0207] The cancer vaccines provided according to the present invention, when administered to a patent, provide one or more T cell epitopes for stimulating, priming and / or expanding T cells specific to the patient's tumor. The T cells are preferably directed against cells expressing the antigen from which the T cell epitope is derived. Thus, the vaccines described herein are preferably capable of inducing or promoting a cellular response, preferably cytotoxic T cell activity, against cancer diseases characterized by the presentation of one or more tumor-associated neo-antigens by class I MHC. The vaccines provided herein target cancer-specific mutations, making them specific to the patient's tumor.

[0208] In the context of the present invention, a vaccine relates to a vaccine that, when administered to a patient, preferably provides one or more T cell epitopes (neoepitopes, suitable neoepitopes, combinations of suitable neoepitopes identified herein), such as 2 or more, 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, preferably up to 60, up to 55, up to 50, up to 45, up to 40, up to 35 or up to 30 T cell epitopes incorporating amino acid modifications or modified peptides predicted to be suitable epitopes. Presentation of these epitopes by the patient's cells, in particular antigen presenting cells, preferably results in T cells targeting the epitopes upon binding to MHC, and thus the patient's tumors, preferably primary tumors and tumor metastases, express the antigens from which the T cell epitopes presented on the MHC are derived and present the same epitopes on the surface of the tumor cells.

[0209] The method of the invention may include further steps to determine the usefulness of the identified amino acid modifications or modified peptides comprising suitable neoepitopes identified herein for cancer vaccination. Thus, further steps may include one or more of the following: (i) assessment of whether the modifications are located in known or predicted MHC-presented epitopes, (ii) in vitro and / or in silico testing of whether the modifications are located in MHC-presented epitopes, e.g. testing whether the modifications are part of the peptide sequence that is processed into and / or presented as an MHC-presented epitope, and (iii) in vitro testing of whether the proposed modified epitope, especially when present in its native sequence configuration, e.g. adjacent to amino acid sequences that also flank said epitope in a naturally occurring protein, and when expressed in an antigen-presenting cell, is able to stimulate T cells, such as T cells of a patient with the desired specificity. Such flanking sequences may comprise 3 or more, 5 or more, 10 or more, 15 or more, 20 or more, preferably up to 50, up to 45, up to 40, up to 35 or up to 30 amino acids, respectively, and may be adjacent to the epitope sequence at the N-terminus and / or C-terminus.

[0210] The modified peptides determined according to the present invention can be ranked according to their usefulness as epitopes for cancer vaccination.Thus, in one aspect, the method of the present invention comprises a manual or computer-based analytical process, in which the identified modified peptides are analyzed and selected according to their usefulness in each vaccine provided.In a preferred embodiment, said analytical process is a computer algorithm-based process.Preferably, said analytical process comprises one or more of the following steps, preferably said analytical method comprises determining and / or ranking epitopes according to their predicted ability to be immunogenic:

[0211] The epitopes identified according to the invention and provided in the vaccine are preferably present in the form of a polypeptide comprising said epitope (neoepitope, suitable neoepitopes, neoepitopes found in a combination of suitable neoepitopes identified herein), such as a polyepitopic polypeptide or a nucleic acid, in particular an RNA, encoding said polypeptide. Furthermore, the epitope may be present in the polypeptide in the form of a vaccine sequence, i.e. adjacent to an amino acid sequence which is similarly adjacent to said epitope in the context of its natural sequence, for example in a protein of natural origin. Such adjacent sequences may comprise 5 or more, 10 or more, 15 or more, 20 or more, preferably up to 50, up to 45, up to 40, up to 35 or up to 30 amino acids, respectively, and may be adjacent to the epitope sequence at the N-terminus and / or C-terminus. Thus, the vaccine sequence may comprise 20 or more, 25 or more, 30 or more, 35 or more, 40 or more amino acids, preferably up to 50, up to 45, up to 40, up to 35 or up to 30. In one embodiment, the epitopes and / or vaccine sequences are arranged head-to-tail in the polypeptide.

[0212] In one embodiment, the epitopes / suitable neoepitopes identified herein and / or vaccine sequences are spaced apart by a linker, in particular a neutral linker. The term "linker" as used in the context of the present invention relates to a peptide added between two peptide domains, such as epitopes or vaccine sequences, to connect said peptide domains. There is no particular restriction regarding the linker sequence. However, it is preferred that the linker sequence reduces steric hindrance between the two peptide domains, translates well, and supports or allows epitope processing. Furthermore, the linker should have no or only few immunogenic sequence elements. The linker should preferably not create non-intrinsic epitopes, such as those resulting from junctional stitching between adjacent epitopes, which may give rise to undesired immune responses. Thus, polyepitope vaccines should preferably contain linker sequences that can reduce the number of undesired MHC-binding junctional epitopes. Hoyt et al. (EMBO J. 25(8), 1720-9, 2006) and Zhang et al. (J. Biol. Chem., 279(10), 8635-41, 2004) have shown that glycine-rich sequences impair proteasomal processing, and therefore the use of glycine-rich linker sequences serves to minimize the number of peptides contained in the linker that are processable by the proteasome. Furthermore, glycine has been observed to inhibit strong binding at MHC binding groove positions (Abastado et al., 1993, J. Immunol. 151(7): 3569-75). Schlessinger et al., 2005, Proteins, 61(1): 115-26, found that the amino acids glycine and serine included in the amino acid sequence result in a more flexible protein that is more efficiently translated and processed by the proteasome, allowing better access to the encoded epitope. The linker may contain 3 or more, 6 or more, 9 or more, 10 or more, 15 or more, 20 or more, preferably up to 50, up to 45, up to 40, up to 35 or up to 30 amino acids, respectively. Preferably, the linker is rich in glycine and / or serine amino acids.Preferably, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the amino acids of the linker are glycine and / or serine. In a preferred embodiment, the linker consists essentially of the amino acids glycine and serine. In one embodiment, the linker is the amino acid sequence (GGS). a (GSS) b (GGG) c (SSG) d (GSG) e wherein a, b, c, d and e are independently numbers selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, and a+b+c+d+e is different from 0 and is preferably 2 or more, 3 or more, 4 or more, or 5 or more. In one embodiment, the linker comprises a sequence as described herein, including the linker sequences described in the Examples, such as the sequence GGSGGGGSG.

[0213] In a particularly preferred embodiment, a polypeptide incorporating one or more suitable neoepitopes identified by the methods herein, such as a polyepitope polypeptide, is administered to the patient in the form of a nucleic acid, preferably an RNA, such as an in vitro transcribed or synthetic RNA, that can be expressed in the patient's cells, such as antigen-presenting cells, to produce a polypeptide. The present invention also envisages administering one or more multiepitope polypeptides, which are encompassed by the term "polyepitope polypeptide" for the purposes of the present invention, preferably in the form of a nucleic acid, preferably an RNA, such as an in vitro transcribed or synthetic RNA, that can be expressed in the patient's cells, such as antigen-presenting cells, to produce one or more polypeptides. When administering multiple multiepitope polypeptides, the suitable neoepitopes provided by the different multiepitope polypeptides may be different or partially overlapping. Once present in the patient's cells, such as antigen-presenting cells, the polypeptide according to the present invention is processed to produce the suitable neoepitopes identified according to the present invention. Administration of the vaccines provided according to the invention may preferably provide MHC class II-presented epitopes capable of inducing a CD4+ helper T cell response against cells expressing the antigen from which the MHC-presented epitope is derived. Alternatively or additionally, administration of the vaccines provided according to the invention may provide MHC class I-presented neoepitopes capable of inducing a CD8+ T cell response against cells expressing the antigen from which the MHC-presented neoepitopes are derived. Furthermore, administration of the vaccines provided according to the invention may provide one or more neoepitopes (including known neoepitopes and suitable neoepitopes identified according to the invention), as well as one or more epitopes that do not contain cancer-specific somatic mutations but are expressed by cancer cells and preferably induce an immune response against the cancer cells, preferably a cancer-specific immune response.In one embodiment, administration of the vaccine provided according to the invention provides neoepitopes capable of inducing CD4+ helper T cell responses against cells expressing MHC class II-presented epitopes and / or antigens from which the MHC-presented epitopes are derived, and epitopes that do not contain cancer-specific somatic mutations and are capable of inducing CD8+ T cell responses against cells expressing MHC class I-presented epitopes and / or antigens from which the MHC-presented epitopes are derived. In one embodiment, the epitopes that do not contain cancer-specific somatic mutations are derived from tumor antigens. In one embodiment, the neoepitopes and epitopes that do not contain cancer-specific somatic mutations have a synergistic effect in the treatment of cancer. Preferably, the vaccine provided according to the invention is useful for polyepitope stimulation of cytotoxic and / or helper T cell responses.

[0214] The vaccines provided according to the present invention may be recombinant vaccines.

[0215] Another type of agent is an immune cell, such as a T cell expressing a T cell receptor, or a T cell recombinantly expressing a T cell receptor or expressing an artificial or chimeric T cell receptor (CAR), which receptor is targeted to an antigen, e.g., a suitable neo-epitope identified by the method of the invention as a suitable disease-specific target, preferably such a neo-epitope is expressed on the surface of the cell in complex with an MHC molecule. Preferably, when the immune cell recognizes the antigen by receptor-antigen binding, the immune cell (immunoreactive cell) is stimulated, primed and / or expanded, or exerts the effector function of the above-mentioned immunoreactive cell.

[0216] The term "antigen-specific T cells" or similar terms relate to T cells that recognize an antigen complexed within an MHC class I molecule, e.g., a suitable neoepitope, and that, after binding to said antigen, preferably exert the effector functions of T cells described above. T cells and other lymphoid cells are considered to be specific for an antigen if they kill a target cell expressing the antigen. T cell specificity can be assessed using any of a variety of standard techniques, e.g., in a chromium release assay or proliferation assay. Alternatively, the synthesis of lymphokines (such as interferon-γ) can be measured.

[0217] T cell receptors and other antigen receptors are described above. The term "CAR" (or "chimeric antigen receptor") refers to an artificial receptor comprising a single molecule or a complex of molecules that can recognize, i.e. bind to, a target structure (e.g., an antigen) in a target cell, such as a cancer cell (e.g., by binding of an antigen binding domain to an antigen expressed on the surface of the target cell), and confer specificity to an immune effector cell, such as a T cell, expressing said CAR on its cell surface. Preferably, recognition of the target structure by the CAR results in activation of the immune effector cell expressing said CAR. A CAR can comprise one or more protein units, said protein units comprising one or more domains described herein. The term "CAR" does not include T cell receptors.

[0218] In one embodiment, a single chain variable fragment (scFv) derived from a monoclonal antibody is fused to the CD3-zeta transmembrane and endodomain. Such a molecule results in the transmission of a zeta signal in response to recognition by the scFv of its antigen target in a target cell and killing of the target cell expressing the target antigen. Antigen recognition domains that can be used similarly include T cell receptor (TCR) alpha and beta single chains, among others. Virtually anything that binds with high affinity to a given target can be used as an antigen recognition domain.

[0219] After antigen recognition, the receptors are clustered and a signal is transmitted to the cell. In this regard, a "T cell signaling domain" is a domain, preferably an endodomain, that transmits an activation signal to T cells after antigen binding. The most commonly used endodomain component is CD3-zeta.

[0220] Adoptive cell transfer therapy with CAR-engineered T cells expressing chimeric antigen receptors is a promising mode of therapy, since CAR-modified T cells can be engineered to target virtually any antigen expressed on diseased cells, such as tumor antigens.Preferably, the tumor antigen is a neo-epitope resulting from a tumor-specific mutation identified by the method of the present invention as a suitable tumor-specific target.For example, a patient's T cells can be genetically engineered (genetically modified) to express a CAR specifically made against a tumor-specific neo-epitope complexed with MHC molecules on the surface of the patient's tumor cells, and then infused back into the patient.

[0221] CARs can replace the function of a T cell receptor, and in particular can confer reactivity, such as cytolytic activity, to cells, such as T cells. However, in contrast to the binding of T cell receptors to antigen peptide-MHC complexes described above, CARs can also bind to antigens, particularly when expressed on the cell surface.

[0222] According to the present invention, a CAR can generally comprise three domains. The first domain is a binding domain that recognizes and binds an antigen. The second domain is a costimulatory domain. The costimulatory domain functions to enhance the proliferation and survival of cytotoxic lymphocytes after binding of the CAR to a targeting moiety. The identity of the costimulatory domain is limited only in that it has the ability to enhance cellular proliferation and survival after binding of the targeting moiety by the CAR. Suitable costimulatory domains include CD28, CD137 (4-1BB), a member of the tumor necrosis factor (TNF) receptor family, CD134 (OX40), a member of the TNFR superfamily of receptors, and CD278 (ICOS), a CD28 superfamily costimulatory molecule expressed on activated T cells. The third domain is an activation signaling domain (or T cell signaling domain). The activation signaling domain functions to activate cytotoxic lymphocytes after binding of the CAR to an antigen. The identity of the activation signaling domain is limited only in that it has the ability to induce activation of selected cytotoxic lymphocytes following binding of the antigen by the CAR. Suitable activation signaling domains include the T cell CD3 [zeta] chain and the Fc receptor [gamma].

[0223] CARs can include three domains together in the form of a fusion protein. Such fusion proteins will generally include a binding domain, one or more costimulatory domains, and an activation signaling domain linked in an N-terminal to C-terminal direction. However, CARs are not limited to this arrangement, and other arrangements are permissible, including a binding domain, an activation signaling domain, and one or more costimulatory domains. It will be understood that since the binding domain must be free to bind to the antigen, the placement of the binding domain in the fusion protein will generally be such that the display of the domain outside the cell is achieved. In the same manner, since the costimulatory and activation signaling domains function to induce the activity and proliferation of cytotoxic lymphocytes, the fusion protein will generally display these two domains inside the cell. CARs can include additional elements such as a signal peptide to ensure proper export of the fusion protein to the cell surface, a transmembrane domain to ensure that the fusion protein is maintained as an integral membrane protein, and a hinge domain (or spacer region) that confers flexibility to the binding domain and allows strong binding to the antigen.

[0224] The cells used in the context of CAR and other artificial antigen receptors are preferably T cells, particularly cytotoxic lymphocytes, preferably selected from cytotoxic T cells, natural killer (NK) cells and lymphokine-activated killer (LAK) cells. After activation, each of these cytotoxic lymphocytes induces the destruction of target cells. For example, cytotoxic T cells induce the destruction of target cells by either or both of the following means: First, after activation, T cells release cytotoxins such as perforin, granzymes and granulysin. Perforin and granulysin create pores in the target cell, and granzymes enter the cell and induce the caspase cascade in the cytoplasm, which induces apoptosis (programmed cell death) of the cell. Second, apoptosis can be induced via Fas-Fas ligand interaction between T cells and target cells. The cytotoxic lymphocytes will preferably be autologous cells, although xenogeneic or allogeneic cells may also be used.

[0225] The binding domain for an antigen that may be present in the CAR has the ability to bind (target) the antigen, i.e., to bind (target) an epitope present in the antigen, preferably to bind (target) a neo-epitope identified by the methods of the present invention as a suitable disease-specific target, the neo-epitope being presented in the context of MHC on the surface of a cell. Preferably, the binding domain for the antigen is specific for the antigen.

[0226] Another type of agent is immune cells, such as lymphoid cells, loaded with peptides containing suitable neo-epitopes identified by the method of the present invention. In a preferred embodiment, the lymphoid cells are dendritic cells. In the context of the present invention, lymphoid cells, preferably isolated from the patient to be treated, are incubated with the antigen to be targeted, and then the incubated cells are administered to the patient to induce an immune response against the cells expressing the antigen. Thus, peptides containing suitable epitopes can be incubated with dendritic cells, and the incubated cells can be administered to induce an immune response against the cells expressing the suitable neo-epitopes.

[0227] The term "recombinant" in the context of the present invention means "created by genetic engineering". Preferably, a "recombinant entity" such as a recombinant polypeptide in the context of the present invention does not occur in nature and is preferably the result of a combination of entities such as amino acid or nucleic acid sequences that are not combined in nature. For example, a recombinant polypeptide in the context of the present invention may contain several amino acid sequences, such as neoepitopes or vaccine sequences derived from different proteins or different parts of the same protein fused together, for example by peptide bonds or suitable linkers.

[0228] As used herein, the term "naturally occurring" refers to an object that can be found in nature. For example, a peptide or nucleic acid that is present in an organism (including viruses), can be isolated from a natural source, and has not been intentionally modified in a laboratory by man is naturally occurring.

[0229] According to the present invention, the term "disease" refers to any pathological condition, including cancer diseases, particularly the forms of cancer diseases described herein.

[0230] The term "normal" refers to a healthy state or the state in a healthy subject or tissue, ie, a non-disease state, where "healthy" preferably means non-cancerous.

[0231] By "disease involving cells expressing an antigen" is meant that expression of the antigen is detected in cells of a diseased tissue or organ. Expression in cells of a diseased tissue or organ may be increased compared to the state of a healthy tissue or organ. Increase refers to at least 10%, in particular at least 20%. At least 50%, at least 100%, at least 200%, at least 500%, at least 1000%, at least 10000% or even more increase. In one embodiment, expression is found only in diseased tissue and expression in healthy tissue is suppressed. According to the present invention, diseases involving or associated with cells expressing an antigen include cancer diseases.

[0232] Cancer (the medical term is malignant neoplasm) is a class of diseases in which groups of cells exhibit uncontrolled growth (division beyond normal limits), invasion (invasion and destruction of nearby tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). The malignant characteristics of these three cancers distinguish them from benign tumors, which are self-limited and do not invade or metastasize. Most cancers form tumors, but some, such as leukemia, do not.

[0233] Malignant tumor is essentially synonymous with cancer. Malignant disease, malignant neoplasm, and malignant tumor are essentially synonymous with cancer.

[0234] According to the present invention, the term "tumor" or "tumor disease" refers to an abnormal growth of cells (called neoplastic cells, tumorigenic cells or tumor cells), preferably forming a swelling or lesion. By "tumor cells" is meant abnormal cells that grow by rapid uncontrolled cell proliferation and continue to grow after the stimulus that initiated the new growth has ceased. Tumors show a partial or complete lack of structural organization and functional coordination with normal tissues and usually form a distinct tissue mass that can be either benign, premalignant or malignant.

[0235] A benign tumor is one that lacks all three of the malignant characteristics of cancer. Thus, by definition, a benign tumor does not grow in an unrestrained invasive manner, does not invade surrounding tissues, and does not spread (metastasize) to non-adjacent tissues.

[0236] A neoplasm is an abnormal mass of tissue that is the result of new formation. Neoplasia (from Greek: new growth) is an abnormal proliferation of cells. The growth of the cells exceeds and is uncoordinated with the growth of the normal tissue around it. The growth continues in the same excessive manner even after the stimulus has ceased. This usually gives rise to a mass or tumor. Neoplasms can be benign, premalignant, or malignant.

[0237] "Tumor growth" or "tumor growth" in the context of the present invention relates to the tendency of a tumor to increase in size and / or the tendency of tumor cells to proliferate.

[0238] For the purposes of the present invention, the terms "cancer" and "cancer disease" are used interchangeably with the terms "tumor" and "tumor disease".

[0239] Cancers are classified according to the type of cells that resemble the tumor, and therefore the type of tissue from which the tumor is presumed to originate: histology and location, respectively.

[0240] The term "cancer" according to the present invention includes leukemia, seminoma, melanoma, teratoma, lymphoma, neuroblastoma, glioma, rectal cancer, endometrial cancer, kidney cancer, adrenal cancer, thyroid cancer, blood cancer, skin cancer, brain cancer, cervical cancer, intestinal cancer, liver cancer, colon cancer, stomach cancer, intestinal cancer, head and neck cancer, gastrointestinal cancer, lymph node cancer, esophageal cancer, colorectal cancer, pancreatic cancer, ear, nose and throat (ENT) cancer, breast cancer, prostate cancer, uterine cancer, ovarian cancer and lung cancer and metastases thereof. Examples are lung carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, renal cell carcinoma, cervical carcinoma or metastases of the above mentioned cancer types or tumors. According to the present invention, the term cancer also includes cancer metastasis and cancer relapse.

[0241] "Metastasis" refers to the spread of cancer cells from their original site to another part of the body. The formation of metastasis is a very complex process, which depends on the detachment of malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the endothelial basement membrane to enter the body cavities and blood vessels, and then infiltration of the target organ after transport by blood. Finally, the growth of new tumors at the target site, i.e. secondary or metastatic tumors, depends on angiogenesis. Tumor metastasis often occurs even after removal of the primary tumor, because tumor cells or components remain and may develop metastatic potential. In one embodiment, the term "metastasis" according to the present invention relates to "distant metastasis", which refers to metastasis away from the primary tumor and regional lymph node system.

[0242] The cells of secondary or metastatic tumors resemble those of the original tumor. This means, for example, that if ovarian cancer metastasizes to the liver, the secondary tumor is made up of abnormal ovarian cells rather than abnormal liver cells. In this case, the tumor in the liver is called metastatic ovarian cancer rather than liver cancer.

[0243] The term "circulating tumor cells" or "CTCs" refers to cells that detach from primary tumors or tumor metastases and circulate in the bloodstream. CTCs may constitute the seeds for subsequent growth of further tumors (metastases) in various tissues. Circulating tumor cells are found at a frequency of about 1-10 CTCs per mL of whole blood in patients suffering from metastatic disease. Research methods have been developed to isolate CTCs. Several research methods for isolating CTCs have been described in the art, for example techniques that use the fact that epithelial cells commonly express the cell adhesion protein EpCAM, which is not present in normal blood cells. Immunomagnetic bead-based capture involves treating blood samples with antibodies against EpCAM conjugated to magnetic particles, followed by separation of tagged cells in a magnetic field. Rare CTCs are then distinguished from contaminating white blood cells by staining the isolated cells with antibodies against another epithelial marker, cytokeratin, and the common white blood cell marker CD45. This robust and semi-automated technique identifies CTCs with a mean yield of approximately 1 CTC / mL and a purity of 0.1% (Allard et al., 2004, Clin Cancer Res 10: 6897-6904). A second method for isolating CTCs uses a microfluidic-based CTC capture device that involves flowing whole blood through a chamber embedded with 80,000 microposts that have been functionalized by coating with an antibody against EpCAM. CTCs are then stained with secondary antibodies against either cytokeratin or tissue-specific markers such as PSA in prostate cancer or HER2 in breast cancer, and visualized by automated scanning of the microposts along three-dimensional coordinates in multiple planes. The CTC-chip is capable of identifying cytokerating-positive circulating tumor cells in patients with a median yield of 50 cells / ml and a purity range of 1-80% (Nagrath et al., 2007, Nature 450: 1235-1239). Another possibility for isolating CTCs is to use the CellSearch™ Circulating Tumor Cell (CTC) test from Veridex, LLC (Raritan, NJ), which captures, identifies, and counts CTCs in a tube of blood.The CellSearch™ system is a US Food and Drug Administration (FDA) approved method for enumerating CTCs in whole blood, and is based on a combination of immunomagnetic labeling and automated digital microscopy. Other methods for isolating CTCs have been described in the literature, all of which can be used in conjunction with the present invention.

[0244] Relapse occurs when a person is again affected by a condition that previously affected them. For example, if a patient suffers from a tumor disease, is successfully treated for said disease, and develops said disease again, the newly developed disease may be considered as a relapse. However, according to the present invention, the relapse of a tumor disease may occur at the site of the original tumor disease, but this is not necessarily the case. Thus, for example, if a patient suffers from an ovarian tumor and is successfully treated, the relapse may be the development of an ovarian tumor or a tumor at a site other than the ovary. Tumor relapse also includes the situation where a tumor develops at a site other than the site of the original tumor and the situation where a tumor develops at the site of the original tumor. Preferably, the original tumor that the patient was treated for is a primary tumor, and the tumor at a site other than the site of the original tumor is a secondary or metastatic tumor.

[0245] The term "immune response" relates to the reaction of the immune system against an immunogenic organism, such as a bacterium or virus, a cell or a substance. The term "immune response" includes the innate immune response and the adaptive immune response. Preferably, the immune response relates to the activation of immune cells, the induction of cytokine biosynthesis and / or antibody production.

[0246] The immune response induced by the composition of the present invention preferably comprises the steps of activation of antigen-presenting cells such as dendritic cells and / or macrophages, presentation of an antigen or a fragment thereof by the antigen-presenting cells, and activation of cytotoxic T cells due to this presentation.

[0247] The term "immune cell" refers to a cell of the immune system that is involved in the defense of an individual's body. The term "immune cell" encompasses specific types of immune cells and their precursors, including white blood cells, including macrophages, monocytes (precursors of macrophages), granulocytes such as neutrophils, eosinophils, and basophils, dendritic cells, mast cells, and lymphocytes such as B cells, T cells, and natural killer (NK) cells. Macrophages, monocytes (precursors of macrophages), neutrophils, dendritic cells, and mast cells are phagocytic cells.

[0248] The term "immunotherapy" relates to the treatment of a disease or condition by induction, enhancement or suppression of an immune response. Immunotherapies designed to induce or amplify an immune response are classified as activating immunotherapies, whereas immunotherapies that reduce or suppress an immune response are classified as suppressing immunotherapies. The term "immunotherapy" includes antigen immunization or vaccination or tumor immunization or vaccination. The term "immunotherapy" also relates to the manipulation of the immune response such that an inappropriate immune response is modulated to a more appropriate response in the context of autoimmune diseases such as rheumatoid arthritis, allergies, diabetes or multiple sclerosis.

[0249] The terms "immunization" or "vaccination" refer to the process of administering an antigen to an individual for the purpose of inducing an immune response, e.g., for therapeutic or prophylactic reasons.

[0250] "Treating" refers to administering a compound or composition described herein to a subject to prevent or eliminate disease, including reducing tumor size or number of tumors in a subject, halting or slowing disease in a subject, inhibiting or slowing the onset of new disease in a subject, reducing the frequency or severity of symptoms and / or recurrence in a subject currently or previously affected by a disease, and / or extending or increasing the lifespan of a subject. In particular, the term "treating a disease" includes curing, shortening the duration, ameliorating, preventing, slowing or inhibiting the progression or worsening, or preventing or slowing the onset of a disease or a symptom thereof.

[0251] "At risk" refers to a subject, i.e., a patient, who is identified as having a higher than normal likelihood of developing a disease, particularly cancer, compared to the general population. Furthermore, a subject who has had or is currently suffering from a disease, particularly cancer, is a subject at increased risk of developing the disease, since such a subject may continue to develop the disease. Also, a subject who currently has or has had cancer is at increased risk of cancer metastasis.

[0252] Prophylactic administration of immunotherapy, such as the prophylactic administration of the composition of the present invention, preferably protects the recipient from developing the disease.Therapeutic administration of immunotherapy, such as the therapeutic administration of the composition of the present invention, can result in the inhibition of disease progression / growth.This includes the slowing down of disease progression / growth, particularly the disruption of disease progression, which preferably results in the elimination of the disease.

[0253] Immunotherapy may be performed using any of a variety of techniques in which the drugs provided herein function to remove diseased cells from a patient. Such removal may occur as a result of enhancing or inducing an immune response in the patient specific to an antigen or cells expressing the antigen.

[0254] In certain embodiments, immunotherapy may be active immunotherapy, in which the treatment relies on in vivo stimulation of the host's endogenous immune system with administration of immune response modifiers (such as the polypeptides and nucleic acids provided herein) to react to diseased cells.

[0255] The drugs and compositions provided herein may be used alone or in combination with conventional treatment regimens such as surgery, radiation, chemotherapy and / or bone marrow transplantation (autologous, syngeneic, allogeneic or unrelated).

[0256] The term "in vivo" refers to a situation within a subject.

[0257] The terms "subject", "individual", "organism" or "patient" refer to vertebrates, particularly mammals. For example, mammals in the context of the present invention are humans, non-human primates, domesticated mammals such as dogs, cats, sheep, cows, goats, pigs, horses, laboratory animals such as mice, rats, rabbits, guinea pigs, as well as caged animals such as zoo animals. These terms also refer to non-mammalian vertebrates such as birds (particularly domesticated birds such as chickens, ducks, geese, turkeys, etc.) and fish (particularly farmed fish, e.g. salmon or catfish). The term "animal" as used herein also includes humans.

[0258] The term "autologous" is used to describe anything derived from the same subject. For example, "autologous transplant" refers to the transplantation of tissue or organs derived from the same subject. Such procedures are advantageous because they overcome immunological barriers that would otherwise result in rejection.

[0259] The term "xenogeneic" is used to describe something that is made up of multiple different elements. As an example, the transfer of bone marrow from one individual into another individual constitutes a xenogeneic transplant. A xenogeneic gene is a gene that is derived from a source other than the subject.

[0260] As part of a composition for immunization or vaccination, one or more agents described herein are preferably administered together with one or more adjuvants to induce or increase an immune response. The term "adjuvant" refers to a compound that prolongs or enhances or accelerates an immune response. The composition of the present invention preferably exerts its effect without the addition of an adjuvant. Nevertheless, the composition of the present application may contain any known adjuvant. Adjuvants include a heterogeneous group of compounds such as oil emulsions (e.g. Freund's adjuvant), inorganic compounds (such as alum), bacterial products (such as Bordetella pertussis toxin), liposomes, and immune stimulating complexes. Examples of adjuvants are monophosphoryl-lipid-A (MPL SmithKline Beecham), QS21 (SmithKline Beecham), DQS21 (SmithKline Beecham, WO 96 / 33739), saponins such as QS7, QS17, QS18, and QS-L1 (So et al., 1997, Mol. Cells 7:178-186), incomplete Freund's adjuvant, complete Freund's adjuvant, vitamin E, montanid, alum, CpG oligonucleotides (Krieg et al., 1995, Nature 374:546-549), and various water-in-oil emulsions prepared from biodegradable oils such as squalene and / or tocopherol.

[0261] Other substances that stimulate the patient's immune response may also be administered. For example, cytokines can be used during vaccination due to their regulatory properties on lymphocytes. Such cytokines include, for example, interleukin-12 (IL-12), which has been shown to increase the protective effect of vaccines (see Hall, 1995, IL-12 at the crossroads, Science 268:1432-1434), GM-CSF and IL-18.

[0262] There are several compounds that enhance the immune response and can therefore be used in vaccination, including costimulatory molecules provided in the form of proteins or nucleic acids, such as B7-1 and B7-2 (CD80 and CD86, respectively).

[0263] According to the present invention, a "tumor sample" is a body sample that contains tumor or cancer cells, such as circulating tumor cells (CTCs), in particular a tissue sample and / or a cellular sample that contains body fluids. According to the present invention, a "non-tumor sample" is a body sample that does not contain tumor or cancer cells, such as circulating tumor cells (CTCs), in particular a tissue sample and / or a cellular sample that contains body fluids. Such body samples can be obtained in a conventional manner, such as by tissue biopsy, including punch biopsy, and by taking blood, bronchial aspirate, sputum, urine, stool or other body fluids. According to the present invention, the term "sample" also includes processed samples, such as fractions or isolates of biological samples, e.g. nucleic acid or cell isolates.

[0264] The therapeutically active agents, vaccines and compositions described herein can be administered by any conventional route, including by injection or infusion. Administration can be performed, for example, orally, intravenously, intraperitoneally, intramuscularly, subcutaneously or transdermally. In one embodiment, administration is performed intranodal, such as by injection into a lymph node. Other modes of administration envisage in vitro transfection of antigen-presenting cells, such as dendritic cells, with the nucleic acids described herein, followed by administration of the antigen-presenting cells.

[0265] The agents described herein are administered in effective amounts. "Effective amount" refers to an amount that alone or together with further doses achieves the desired reaction or the desired effect. In the case of the treatment of a particular disease or a particular condition, the desired reaction preferably relates to the inhibition of the course of the disease. This includes the delay of the progression of the disease, in particular the halting or reversal of the progression of the disease. The desired reaction in the treatment of a disease or condition may also be the delay of the onset or the prevention of the onset of said disease or said condition.

[0266] The effective amount of the agents described herein depends on the condition to be treated, the severity of the disease, the individual parameters of the patient, including age, physiological state, size and weight, duration of treatment, type of concomitant treatment (if any), specific route of administration and similar factors. Thus, the dosage of the agents described herein may vary depending on such parameters. If the initial dose is insufficient to produce a response in the patient, a higher dosage (or an effectively higher dosage achieved by a different, more localized route of administration) may be used.

[0267] The term "pharmaceutical acceptable" refers to the non-toxicity of a material that does not interact with the action of the active ingredients of the pharmaceutical composition.

[0268] Pharmaceutical compositions of the invention may contain salts, buffers, preservatives, carriers and optionally other therapeutic agents. Preferably, pharmaceutical compositions of the invention include one or more pharma- ceutically acceptable carriers, diluents and / or excipients.

[0269] The term "excipient" is intended to indicate any substance in a pharmaceutical composition that is not an active ingredient, such as a binder, lubricant, thickener, surface active agent, preservative, emulsifier, buffer, flavoring or coloring agent, etc.

[0270] The term "diluent" refers to a diluting and / or thinning agent. Further, the term "diluent" includes any one or more of a fluid, liquid or solid suspension and / or mixed medium.

[0271] The term "carrier" refers to one or more compatible solid or liquid fillers or diluents suitable for administration to humans. The term "carrier" refers to a natural or synthetic organic or inorganic component that is combined with the active ingredient to facilitate the application of the active ingredient. Preferably, the carrier component is a sterile liquid such as water or oil, including mineral oils, animal or vegetable derived oils, such as peanut oil, soybean oil, sesame oil, sunflower oil, etc. Salt solutions and aqueous dextrose and glycerin solutions can also be used as aqueous carrier compounds.

[0272] Pharmaceutically acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical arts and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R Gennaro, ed., 1985). Examples of suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter, and the like. Examples of suitable diluents include ethanol, glycerol, and water.

[0273] The pharmaceutical carrier, excipient or diluent may be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions of the present invention may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder, lubricant, suspending agent, coating agent and / or solubilizing agent. Examples of suitable binders include starch, gelatin, glucose, anhydrous lactose, free flowing lactose, beta-lactose, natural sugars such as corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and others. Preservatives, stabilizers, dyes and even flavorings may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may also be used.

[0274] In one embodiment, the composition is an aqueous composition. The aqueous composition can optionally contain solutes, such as salts. In one embodiment, the composition is in the form of a freeze-dried composition. The freeze-dried composition can be obtained by freeze-drying the respective aqueous composition.

[0275] The agents and compositions provided herein can be used alone or in combination with other therapeutic regimens, such as surgery, radiation, chemotherapy and / or bone marrow transplantation (autologous, syngeneic, allogeneic or unrelated).

[0276] The present invention has been detailed and explained by means of figures and examples, which are used for illustrative purposes only and are not intended to be limiting. Thanks to the descriptions and examples, further embodiments are accessible to those skilled in the art that are also encompassed by the present invention. [Brief description of the drawings]

[0277] [Figure 1a] A glioblastoma sample with a highly localized amplification of the epidermal growth factor receptor gene (EGFR). Graphical representation of the local genes surrounding EGFR on chromosome 7. [Figure 1b] A glioblastoma sample with a highly focal amplification of the epidermal growth factor receptor gene (EGFR). List of the 12 single nucleotide variations with the highest absolute copy numbers. [Diagram 2] List of multiple genes with disease-specific mutations in melanoma samples sorted by zygosity (Cx). [Diagram 3] List of a number of genes from melanoma samples in which all copies have a disease-specific mutation (zygosity ratio equal to 1), of which three genes are essential genes in humans or suspected to be essential genes in humans. Abbreviations in the figure: chr_pos, chromosome location; CN, absolute copy number; Cx, zygosity status; EC, error correction for absolute copy number; VAF, variant allele frequency; rho, estimated percent of tumor cells containing the mutated allele (SNV); FLRT+u, confidence score for the mutation; site classification is the confidence class of the mutation; essential genes; Y, if the gene is found to be essential. Example 1

[0278] Targeting disease-specific mutations in genes with high copy number Genomic information on glioblastoma samples (Chin et al., 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature 455:1061-1068) was analyzed by searching for genes that had high copy numbers and where at least one copy of the gene contained a disease-specific mutation. Quality analysis showed that there was high fidelity of copy number assignment for the 11,574 individual genes analyzed, and the ploidy of the genome of the sample was determined to be 1.95. Figure 1a shows a graphical representation of the local genes surrounding the epidermal growth factor receptor (EGFR) on chromosome 7, which was a known driver gene and target for treatment. It was shown that EGFR in this genome had an error-corrected absolute copy number of 76, of which 13 copies contained disease-specific single nucleotide variations. Figure 1b provides a list of genes in this genomic sample with the highest absolute copy numbers. There are four additional genes with absolute copy numbers greater than 2. Indeed, EGFR amplification is a known genetic hallmark of primary glioblastoma (Benito et al., 2009, Neuropathology 30 (4):392-400), and this gene has been considered as a target for treatment (Taylor, 2012, Curr Cancer Drug Targets. Mar; 12(3):197-209). Example 2

[0279] Targeting disease-specific mutations with hyperzygosity Exomes from samples of melanoma cells from human tumors were analyzed by searching for genes in which at least one copy of the gene has a disease-specific mutation, focusing on the number of copies of the gene with the disease-specific mutation and the total number of copies of the gene, whether the gene has a mutation or not. Figure 2 provides a list of genes sorted by zygosity state, where the disease-specific mutation is found in multiple copies of the gene. For example, the disease-specific mutation in the OXGR1 gene has the highest zygosity state (4), and also has the highest zygosity rate of 4 / 5 or 0.8, notably because there are a total of 5 copies of the OXGR1 gene, 4 of which contain the disease-specific mutation. The list provides 10 additional genes in which 3 copies of the gene have a mutation out of a total of 4 copies, showing that the disease-specific mutation in these genes has a zygosity rate of 3 / 4 or 0.75. The remaining listed genes have mutations with a zygosity rate of 2 / 3 or 0.66, since 2 copies out of a total of 3 copies have the mutation. Example 3

[0280] Targeting disease-specific mutations present in all copies of essential genes Exomes from samples of melanoma cells from human tumors were analyzed by searching for genes in which all copies of the gene have the same disease-specific mutation and determining which of these genes are essential genes. These genes were determined to be essential by inferring their degree of essentiality in humans from the knowledge that they are essential in mice (Georgi et al., 2013, From mouse to human: evolutionary genomics analysis of human orthologs of essential genes, PLoS Genetics 9 (5):e1003484; Liao et al., 2007, Mouse duplicate genes are as essential as singletons, Trends Genet. 23:378-381). Figure 3 lists a number of genes in which all copies of the gene have the same disease-specific mutation. Additionally, three highlighted genes were determined to be essential by inferring their degree of essentiality from mouse data.

Claims

1. A method for determining the suitability of a neoepitope resulting from a disease-specific mutation in an allele (mutated allele) in a gene as a disease-specific target, the method comprising a step of determining the copy number of the mutated allele encoding the neoepitope in a diseased cell or a population of diseased cells.

2. 2. The method of claim 1, wherein a high copy number of the mutated allele indicates suitability of the neoepitope as a disease-specific target.

3. The method of claim 2, wherein the higher the copy number of the mutated allele, the more suitable the neoepitope is as a disease-specific target.

4. The method of claim 1, wherein a copy number of the mutated allele greater than two indicates suitability of the neoepitope as a disease-specific target.

5. 5. The method of claim 4, wherein the copy number of the mutated allele is greater than 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 or greater than 100 indicates suitability of the neoepitope as a disease-specific target.

6. 6. The method of any one of claims 1 to 5, wherein the mutated allele is found in a high proportion of copies of the gene, at least one copy of which has the mutated allele (zygosity rate), the zygosity rate being the ratio of the number of copies of the mutated allele to the total number of copies of the nucleotide site to which the mutation is mapped.

7. The method of claim 6, wherein the higher the conjugation rate, the more suitable the neoepitope is as a disease-specific target.

8. 8. The method according to claim 6 or 7, wherein the bonding ratio is greater than 0.5, preferably the bonding ratio is 1.

9. 9. The method of any one of claims 1 to 8, wherein the copy number and / or zygosity rate of the mutated allele and / or the total number of copies of the nucleotide site to which the mutated allele maps are found in a high proportion of diseased cells.

10. The method of claim 9, wherein the higher the proportion of diseased cells that have the mutated allele copy number and / or zygosity rate and / or total number of copies of the nucleotide site to which the mutated allele maps, the higher the suitability of the neoepitope as a disease-specific target.

11. 11. The method of claim 9 or 10, wherein the proportion of diseased cells is 1.

12. 12. The method of any one of claims 1 to 11, wherein the gene is a driver gene whose expression leads to the transformation of a cell to a cancerous phenotype or whose lack of expression leads to the cancerous cell losing its cancerous phenotype.

13. 12. The method of any one of claims 1 to 11, wherein the gene is an essential gene.

14. 14. The method of claim 13, wherein the essential gene is a gene whose silenced or reduced expression at least results in growth deficiency or reduced fitness in the cell in which the essential gene is expressed, preferably in the diseased cell.

15. 14. The method of claim 13, wherein the essential gene is expressed in a wide variety of different tissues and is expressed with a minimum RPKM threshold above 0.

16. A method for determining the suitability of a neoepitope resulting from a disease-specific mutation in a gene as a disease-specific target, the method comprising determining the copy number in a diseased cell or population of diseased cells of a gene, at least one copy of which has the disease-specific mutation.

17. 17. The method of claim 16, wherein a high copy number of the gene indicates its suitability as a disease-specific target for the neoepitope.

18. 18. The method of claim 16 or 17, wherein the higher the copy number of the gene, the more suitable the neoepitope is as a disease-specific target.

19. 19. The method of any one of claims 16 to 18, wherein the gene is a driver gene whose expression leads to the transformation of a cell to a cancerous phenotype or whose lack of expression leads to the cancerous cell losing its cancerous phenotype.

20. 20. The method of any one of claims 16 to 19, wherein the copy number of the gene is found in a higher proportion in diseased cells.

21. 21. The method of claim 20, wherein the higher the proportion of diseased cells that have the copy number, the more suitable the neoepitope is as a disease-specific target.

22. 22. The method of claim 20 or 21, wherein the proportion of diseased cells is 1.

23. 23. The method of any one of claims 1 to 22, wherein the copy number is an absolute copy number.

24. 24. The method of claim 23, wherein the absolute copy number is an error-corrected absolute copy number.

25. 25. The method of claim 23 or 24, wherein the absolute copy number or the error-corrected absolute copy number is normalized to the ploidy, preferably the ploidy of the genome of the affected cell, or the ploidy of the chromosome or part of the chromosome in which the mutation or mutated gene is located in the affected cell.

26. A method for determining the suitability of a neoepitope resulting from a disease-specific mutation in a gene as a disease-specific target, the method comprising determining whether the gene having the disease-specific mutation is an essential gene in a diseased cell or a population of diseased cells.

27. 27. The method of claim 26, wherein the essential gene is a gene whose silenced or reduced expression at least results in impaired growth or reduced fitness of the cell in which the essential gene is expressed, preferably the affected cell.

28. 27. The method of claim 26, wherein the essential gene is expressed in a wide variety of different tissues and is expressed with a minimum RPKM threshold above 0.

29. 29. The method of any one of claims 26 to 28, wherein the gene is an essential gene and all copies of the essential gene carry a disease-specific mutation, indicating suitability as a disease-specific target for the neoepitope.

30. 30. The method of any one of claims 26 or 29, wherein a high proportion of diseased cells and all copies of the essential gene contain a copy of the essential gene with a disease-specific mutation.

31. 31. The method of claim 30, wherein the higher the proportion of diseased cells in which all copies of the essential gene contain copies of the essential gene with a disease-specific mutation, the more suitable the neoepitope is as a disease-specific target.

32. 32. The method of claim 30 or 31, wherein the proportion of diseased cells is 1.

33. A method for determining the suitability of a combination of at least two neoepitopes resulting from disease-specific mutations in at least two genes as a disease-specific target combination, the method comprising a step of determining whether the combination of at least two genes, each having a disease-specific mutation, is a synthetic lethal or synthetic disease gene.

34. 34. The method of claim 33, wherein a combination of at least two genes is synthetically lethal or synthetically diseased, indicating the suitability of the neoepitope combination as a disease-specific target combination.

35. 35. The method of claim 33 or 34, wherein all copies of at least two genes have the disease-specific mutation.

36. 36. The method of claim 35, wherein the diseased cells contain at least two genes with a high proportion of disease-specific mutations.

37. 37. The method of claim 36, wherein the proportion of diseased cells is 1.

38. 38. The method of any one of claims 1 to 37, wherein the disease-specific mutation is a single nucleotide variation.

39. 39. The method of any one of claims 1 to 38, wherein the disease is cancer.

40. 40. The method of any one of claims 1 to 39, wherein the neoepitope is identified by a method comprising sequencing the genome or a portion thereof of the diseased cell.

41. 41. The method of any one of claims 1 to 40 for use in the manufacture of a medicament.

42. 41. The method of any one of claims 1 to 40 for use in the manufacture of a vaccine.

43. 43. The method of claim 42, wherein the vaccine is derived from one or more suitable neoepitopes or a combination of suitable neoepitopes.

44. 44. The method of claim 42 or 43, wherein the vaccine comprises a peptide or polypeptide comprising one or more suitable neoepitopes or a combination of suitable neoepitopes, or a nucleic acid encoding said peptide or polypeptide.

45. 41. A method for providing a vaccine, comprising identifying a suitable neoepitope or a combination of suitable neoepitopes according to the method of any one of claims 1 to 40.

46. 46. ​​The method of claim 45, wherein the vaccine comprises a peptide or polypeptide comprising one or more suitable neoepitopes or a combination of suitable neoepitopes, or a nucleic acid encoding said peptide or polypeptide.

47. 47. A vaccine produced by the method of any one of claims 42 to 46.

48. 41. The method of any one of claims 1 to 40 for use in producing recombinant immune cells expressing an antigen receptor targeted to a suitable neoepitope, or one neoepitope in a combination of suitable neoepitopes.

49. 49. The method of claim 48, wherein the immune cell is a T cell and the antigen receptor is a T cell receptor.

50. 41. A method for providing a recombinant immune cell targeted to a suitable neoepitope, or to one epitope in a combination of suitable neoepitopes, comprising transfecting the immune cell with a recombinant antigen receptor targeted to a suitable neoepitope, or to one epitope in a combination of suitable epitopes, identified by the method of any one of claims 1 to 40.

51. 51. The method of claim 50, wherein the immune cell is a T cell and the antigen receptor is a T cell receptor.

52. 52. A recombinant immune cell produced by the method of any one of claims 48 to 51.

53. 1. A method for generating an immune response in a mammal against a target cell population or target tissue expressing one or more neoepitopes, comprising: (a) administering to a mammal one or more immune cells expressing one or more antigen receptors targeted to one or more neoepitopes identified according to the method of any one of claims 1 to 40; (b) administering a nucleic acid encoding one or more of the neoepitopes identified according to the method of any one of claims 1 to 40; or (c) administering a peptide or polypeptide comprising one or more of the neoepitopes identified according to the method of any one of claims 1 to 40. A method comprising:

54. 54. The method of claim 53, wherein the immune cell is a T cell and the antigen receptor is a T cell receptor.

55. 55. The method of claim 53 or 54, wherein the immune response is a T cell-mediated immune response.

56. 56. The method of any one of claims 53 to 55, wherein the immune response is an anti-tumor immune response and the target cell population or target tissue expressing one or more suitable neoepitopes is a tumor cell or tumor tissue.

57. 1. A method for treating a mammal having a disease, disorder, or condition associated with expression of a neoepitope, comprising: (a) administering to a mammal one or more immune cells expressing one or more antigen receptors targeted to one or more neoepitopes identified according to the method of any one of claims 1 to 40; (b) administering a nucleic acid encoding one or more of the neoepitopes identified according to the method of any one of claims 1 to 40; or (c) administering a peptide or polypeptide comprising one or more of the neoepitopes identified according to the method of any one of claims 1 to 40. A method comprising:

58. 58. The method of claim 57, wherein the immune cell is a T cell and the antigen receptor is a T cell receptor.

59. 59. The method of claim 57 or 58, wherein the disease, disorder or condition is cancer.

Citation Information

Patent Citations

  • Personalized cancer vaccines

    JP2014523406A

  • Selection of neoepitopes as disease-specific targets for therapeutics with enhanced efficacy

    JP7171543B2

  • CH-4010、

  • Method for determining copy number

    EP2002016B1

  • Improved alzheimer's diagnosis

    EP2198292A1